

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2019244479 B2**

(54) Title
Micro RNA expression constructs and uses thereof

(51) International Patent Classification(s)
C12N 15/113 (2010.01)

(21) Application No: **2019244479** (22) Date of Filing: **2019.04.01**

(87) WIPO No: **WO19/186274**

(30) Priority Data

(31) Number	(32) Date	(33) Country
62/650,387	2018.03.30	US
62/650,403	2018.03.30	US

(43) Publication Date: **2019.10.03**

(44) Accepted Journal Date: **2024.12.19**

(71) Applicant(s)
University of Geneva;Les Hopitaux Universitaires de Geneve;University of Zurich

(72) Inventor(s)
KRAUSE, Karl-Heinz;ROUSSET, Francis;SALMON, Patrick;ALESSANDRINI, Marco;SPECK, Roberto;BREDL, Simon;MLAMBO, Tafadzwa;MYBURGH, Renier

(74) Agent / Attorney
Pizzeys Patent and Trade Mark Attorneys Pty Ltd, GPO Box 1374, Brisbane, QLD, 4001, AU

(56) Related Art
**RENIER MYBURGH ET AL: "Optimization of Critical Hairpin Features Allows miRNA-based Gene Knockdown Upon Single-copy Transduction", MOLECULAR THERAPY-NUCLEIC ACIDS, vol. 3, 28 October 2014, p207, ISSN: 2162-2531, DOI: 10.1038/mtna.2014.58
WO 2018/057855 A1
CN 101993992 A**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
03 October 2019 (03.10.2019)



(10) International Publication Number
WO 2019/186274 A3

(51) International Patent Classification:

C12N 15/113 (2010.01)

(21) International Application Number:

PCT/IB2019/000328

(22) International Filing Date:

01 April 2019 (01.04.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/650,403 30 March 2018 (30.03.2018) US
62/650,387 30 March 2018 (30.03.2018) US

(71) Applicants: **UNIVERSITY OF GENEVA** [CH/CH];
24, Rue Du General-dufour, 1211 Geneve (CH).
LES HOPITAUX UNIVERSITAIRES DE GENEVE
[CH/CH]; 4 Rue Gabrielle-Perret-Gentil, 1205 Geneve
(CH). **UNIVERSITY OF ZURICH** [CH/CH]; Prorektorat
MNW, Rämistrasse 71, 8006 Zurich (CH).

(72) Inventors: **KRAUSE, Karl-Heinz**; c/o University Of
Geneva, 24, Rue Du Général-Dufour, 1211 Geneve 4 (CH).
ROUSSET, Francis; c/o University Of Geneva, 24, Rue Du
Général-Dufour, 1211 Geneve 4 (CH). **SALMON, Patrick**;
c/o University Of Geneva, 24, Rue Du Général-Dufour,
1211 Geneve 4 (CH). **ALESSANDRINI, Marco**; c/o Uni-
versity Of Geneva, 24, Rue Du Général-Dufour, 1211 Gene-
ve 4 (CH). **SPECK, Roberto**; c/o University Of Zurich,
Prorektorat MNW, Rämistrasse 71, 8006 Zurich (CH).
BREDL, Simon; c/o University Of Zurich, Prorektorat
MNW, Rämistrasse 71, 8006 Zurich (CH). **MLAMBO,**
Tafadzwa; c/o University Of Zurich, Prorektorat MNW,
Rämistrasse 71, 8006 Zurich (CH). **MYBURGH, Renier**;
c/o University Of Zurich, Prorektorat MNW, Rämistrasse
71, 8006 Zurich (CH).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

05 December 2019 (05.12.2019)

(54) Title: MICRO RNA EXPRESSION CONSTRUCTS AND USES THEREOF

(57) Abstract: The present disclosure relates to miRNA expression constructs, such as for expression of multiple miRNAs and use thereof to knockdown target gene expression. In some aspects, the expression constructs include a promoter element, a spacer sequence and a miRNA coding sequence. In some aspects, constructs provide enhanced immune cell function.



WO 2019/186274 A3

DESCRIPTION

MICRO RNA EXPRESSION CONSTRUCTS AND USES THEREOF

[0001] This application claims the benefit of United States Provisional Patent
5 Application No. 62/650,403, filed March 30, 2018 and United States Provisional Patent
Application No. 62/650,387 filed March 30, 2018, the entirety of which is incorporated herein
by reference.

INCORPORATION OF SEQUENCE LISTING

[0002] The sequence listing that is contained in the file named
10 "UGEN.P0020WO_ST25.txt", which is 20 KB (as measured in Microsoft Windows) and was
created on April 1, 2019, is filed herewith by electronic submission and is incorporated by
reference herein.

BACKGROUND OF THE INVENTION

1. Field of the Invention

15 [0003] The present invention relates generally to the field of molecular biology. More
particularly, it concerns vectors for the expression of miRNAs and the use thereof.

2. Description of Related Art

[0004] The discovery and characterization of miRNA (miRNA) genes and their
regulatory mechanisms not only provided a novel understanding of physiological regulation of
20 gene expression, but also opened new possibilities for miRNA-based therapeutics. The
centerpiece of miRNA genes is a hairpin that ultimately will give rise to a ribonucleoprotein
complex which knocks down expression of target genes through identification and destruction
of its transcript. Structural elements of the hairpin provide a signal for processing by DROSHA
and DICER, leading to formation of a ~20-23bp mature miRNA duplex (Winter *et al.*, 2009).
25 The functional strand of mature miRNA duplex is incorporated into the RISC complex, which
facilitates target mRNA recognition and eventually gene knockdown. Synthetic miRNAs as
well as byproducts of the miRNA pathway, such as short hairpin RNAs (shRNAs) and small
interfering RNAs (siRNAs) are now commonly used tools in molecular biology. However, the
pathway has not lived up to its therapeutic potential (Sullenger and Nair, 2016). siRNAs are
30 most advanced in clinics, however they are short-lived and not suitable for long term gene

correction. shRNAs, which bypass DROSHA processing, may overload the cytoplasm with double stranded RNA and hence lead to toxicity by obstructing the natural miRNA pathway (Boudreau *et al.*, 2009; Grimm, 2011). Synthetic miRNAs mimic the natural pathway and should therefore overcome the above limitations (Maczuga *et al.*, 2013), but their use might be limited due to a relatively weak knockdown activity of miRNA, as compared to shRNAs (Boudreau *et al.*, 2008).

[0005] Lentiviral vectors can be used to express synthetic miRNA genes since genomic integrations of the transgene and long term expression in recipient cells have to date been shown to be safe in patients (Aiuti, *et al.*, 2013; Biffi *et al.*, 2013). However, further research is needed to optimize knockdown by synthetic miRNA genes to the extent that allows efficient therapeutic correction of pathological gene expression.

[0006] The architecture of synthetic miRNA genes, including the tridimensional structure of the hairpin, is of crucial importance for the knockdown efficiency (Myburgh *et al.*, 2014; Fowler *et al.*, 2016). The length of the lower stem is crucial for efficient processing by DROSHA and the relative abundance of mature miRNA strands available, resulting in increased target gene knockdown. However, the architecture of the miRNA gene is not limited to the hairpin structure. Other important elements include promoters and nucleotide sequences not directly linked to the hairpin, referred to as a “spacer”. miRNA genes are most of the time driven by polII-dependent promoters which allow tissue specific or/and inducible expression (Lee *et al.*, 2004; Giry-Laterriere *et al.*, 2011; Giry-Laterriere *et al.*, 2011; Liu *et al.*, 2013). The presence of a spacer appears to enhance knockdown efficiency (Stegmeier *et al.*, 2005), however it is not known whether sequence length or other biophysical parameters of the spacer are of importance.

[0007] Natural miRNA genes occur in a concatenated form, their architecture consists of an arrangement of several hairpins under the control of a single promoter (Bourhill *et al.*, 2016). Such concatenation may be potentially a powerful tool for biotechnology (Sun *et al.*, 2006). There may be an intervening sequence between the miRNA hairpins which separates them spatially, and may be of any sequence desired.

[0008] Adoptive cell therapy (ACT), and in particular the use of T cell receptor (TCR) engineered and chimeric antigen receptor (CAR) T cells, holds great promise for the treatment of various cancers and viral infections. Extremely high cure rates have been reported for certain

cancers, specifically hematological malignancies (Jackson *et al.*, 2016), while limited success has been seen with other malignancies, specifically solid tumors (O'Hara, 2016; Han *et al.*, 2017; Irving *et al.*, 2017). Many of these failures are attributed to a hostile tumor microenvironment which provides physical, molecular and immunosuppressive barriers for the engineered immune cells to overcome. Likewise, to date, constructs that can be used for stimulating an immune cell activity, or inhibiting immune checkpoints have not been developed.

SUMMARY OF THE INVENTION

[0009] In some embodiments the present disclosure provides a miRNA expression construct comprising a promoter element, a spacer at least 50 nucleotides in length, and a miRNA hairpin. In some aspects, the spacer is between 50 and 1,000 nucleotides in length. In some aspects, the spacer is between 50 and 900; 50 and 800; 100 and 800; 150 and 800; 150 and 750; 200 and 750; 200 and 700; 250 and 700; 250 and 650; 300 and 600; 300 and 550; or 300 and 500 nucleotides in length. In some aspects, the spacer is at least 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 365, 370, or 375 nucleotides in length. In some aspects, the spacer is heterologous with respect to the promoter element. In some aspects, the spacer comprises an encoded open reading frame.

[0010] A promoter element in accordance with the embodiments may be a eukaryotic promoter. In some aspects, the eukaryotic promoter is a Pol II or Pol III promoter. In certain aspects, the eukaryotic promoter is a Pol II promoter. In some aspects, the promoter is an inducible, tissue-specific-or cell lineage-specific promoter. In certain aspects, the promoter element is selected from the promoter elements of Table 1. In some aspects, the promoter element is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical the EF1 α promoter. In some aspects, the EF1 α promoter is a splice variant of the EF1 α promoter. In some aspects, the splice variant of the EF1 α promoter is EF1s. In some aspects, the EF1s promoter has a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 45. In some aspects, the EF1s promoter has a sequence 100% identical to SEQ ID NO: 45.

[0011] A spacer in accordance with the embodiments may be selected from the spacers in Table 9. In some aspects, the spacer is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 46. In certain aspects, the spacer is 100% identical to SEQ ID NO: 46. In some aspects, the spacer is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 47. In particular aspects, the spacer is identical to SEQ ID NO: 47. In some aspects, the spacer is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 48. In particular aspects, the spacer is identical to SEQ ID NO: 48. In some aspects, the spacer is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 49. In particular aspects, the spacer is identical to SEQ ID NO: 49.

[0012] An miRNA hairpin in accordance with the embodiments may comprise, from 5' to 3', and in the order from (a)-(g): (a) a mir-16 flanking sequence comprising the sequence of SEQ ID NO: 25; (b) a first lower stem sequence comprising the mir-16 sequence of SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29 or SEQ ID NO: 30; (c) an anti-sense target sequence 22 nucleotides in length; (d) a mir-30 loop sequence comprising the sequence of SEQ ID NO: 31; (e) a sense sequence wherein the sequence is complementary to the sequence of (c) except that the sequence comprises one or two mismatches relative to the sequence of (c), wherein the one or two mismatches comprise: i) a mismatch located at the position 8 to 14 of the sense sequence; or ii) a mismatch at the final 3' position (position 22) of the sense sequence; (f) a second lower stem sequence wherein the sequence is complementary to the sequence of (b); and (g) a second flanking sequence. In some aspects, the sense sequence (e) of the miRNA hairpin comprises one mismatch relative to sequence (c) located at nucleotide position 11 of the sense sequence (e). In some aspects, the sense sequence (e) of the miRNA hairpin comprises two mismatches relative to sequence (c) located (i) at position 11 of the sense sequence (e) and (ii) at the last 3' nucleotide (position 22) of the sense sequence (e). In some aspects, the flanking sequence (g) is not complementary to the mir-16 flanking sequence (a). In certain aspects, the miRNA hairpin sequence is selected from the sequences listed in Table 6. In some aspects, the antisense target sequence is complementary to a CCR5 mRNA sequence. In some aspects, the miRNA expression construct comprises at least 2 repeats of the miRNA hairpin. In some aspects, the at least 2 repeats are separated by

an intervening sequence. In some aspects, the miRNA expression construct is DNA. In some aspects, the miRNA expression construct is RNA.

[0013] In some embodiments, the present disclosure provides an expression vector comprising a miRNA expression construct comprising a promoter element, a spacer at least 50
5 nucleotides in length, and a miRNA hairpin. In some aspects, the expression vector comprises 2 or more copies of the miRNA expression construct. In some aspects, the 2 or more copies of the miRNA expression construct form a polycistronic transcript coding sequence. In some aspects, the expression vector is a viral vector. In some aspects, the viral vector is an adenovirus, adeno-associated virus, retrovirus, or lentivirus vector. In further aspects, the
10 expression vector comprises at least one drug resistance marker.

[0014] In some embodiments, the present disclosure provides a host cell comprising a miRNA expression construct comprising a promoter element, a spacer at least 50 nucleotides in length, and a miRNA hairpin, or an expression vector comprising the miRNA expression construct.

[0015] In some embodiments, the present disclosure provides a method for reducing
15 expression of a gene in a cell comprising expressing a miRNA expression construct comprising a promoter element, a spacer at least 50 nucleotides in length, and a miRNA hairpin, wherein the miRNA hairpin comprises: (a) a mir-16 flanking sequence comprising the sequence of SEQ ID NO: 25; (b) a first lower stem sequence comprising the mir-16 sequence of SEQ ID NO:
20 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29 or SEQ ID NO: 30; (c) an anti-sense target sequence 22 nucleotides in length; (d) a mir-30 loop sequence comprising the sequence of SEQ ID NO: 31; (e) a sense sequence wherein the sequence is complementary to the sequence of (c) except that the sequence comprises one or two mismatches relative to the sequence of (c), wherein the one or two mismatches comprise: i) a mismatch located at the
25 position 8 to 14 of the sense sequence; or ii) a mismatch at the final 3' position (position 22) of the sense sequence; (f) a second lower stem sequence wherein the sequence is complementary to the sequence of (b); and (g) a second flanking sequence; and wherein the anti-sense target sequence (c) is complementary to the sense strand of the gene. In some aspects, expressing the miRNA expression construct in the cell comprises transfecting the cell
30 with a nucleic acid comprising the miRNA expression construct. In some aspects, expressing the miRNA expression construct comprises expressing the miRNA expression construct from an expression vector. In some aspects, the expression vector is an adenovirus, adeno-associated

virus, retrovirus or lentivirus vector. In some aspects, the gene to be silenced is CCR5. In some aspects, the cell is a human cell. In some aspects, the method is an *in vivo* method. In other aspects, the method is an *in vitro* or *ex vivo* method. In some aspects, the method further comprises transplanting the cell expressing the miRNA expression construct into an organism.

5 In some aspects, the cell is comprised within an organism.

[0016] In some embodiments, the present disclosure provides a recombinant nucleic acid molecule comprising a promoter element, a spacer at least 50 nucleotides in length, and at least one miRNA hairpin, the miRNA hairpin from 5' to 3' comprising in the order from (a)-(g): (a) a mir-16 flanking sequence; (b) a first lower stem sequence comprising a mir-16
10 sequence; (c) an anti-sense target sequence 22 nucleotides in length; (d) a mir-30 loop sequence; (e) a sense sequence wherein the sequence is complementary to the sequence of (c) except that the sequence comprises one or two mismatches relative to the sequence of (c), wherein the one or two mismatches comprise: i) a mismatch located at the position 8 to 14 of the sense sequence; or ii) a mismatch at the final 3' position (position 22) of the sense sequence;
15 (f) a second lower stem sequence wherein the sequence is complementary to the sequence of (b), wherein the lower stem is at least 11 nucleotides in length; and (g) a second flanking sequence. In some aspects, the lower stem is 11, 12, 13, 14, 15, 16, or 17 nucleotides in length. In some aspects, the first lower stem (b) comprises the mir-16 sequence of SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29 or SEQ ID NO: 30. In some aspects, the
20 mir-16 flanking sequence (a) comprises the sequence of SEQ ID NO: 25. In some aspects, the mir-30 loop sequence comprises the sequence of SEQ ID NO: 31. In some aspects, the sense sequence (e) comprises one mismatch relative to sequence (c) located at nucleotide position 11 of the sense sequence (e). In some aspects, the sense sequence (e) comprises two mismatches relative to sequence (c) located (i) at position 11 of the sense sequence (e) and (ii) at the last 3'
25 nucleotide (position 22) of the sense sequence (e). In some aspects, the second flanking sequence (g) is not complementary to the mir-16 flanking sequence (a). In some aspects, the miRNA hairpin sequence is selected from the sequences listed in Table 6. In some aspects, the recombinant nucleic acid molecule comprises at least 2 repeats of the sequences (a)-(g). In some aspects, the at least 2 repeats are separated by an intervening sequence. In some aspects,
30 the anti-sense target sequence is complementary to a CCR5 mRNA sequence. In some aspects, the recombinant nucleic acid molecule is RNA. In some aspects, the recombinant nucleic acid molecule is DNA.

[0017] In some embodiments, the present disclosure provides an expression vector comprising a recombinant nucleic acid molecule comprising a promoter element, a spacer at least 50 nucleotides in length, and at least one miRNA hairpin, the miRNA hairpin from 5' to 3' comprising in the order from (a)-(g): (a) a mir-16 flanking sequence; (b) a first lower stem sequence comprising a mir-16 sequence; (c) an anti-sense target sequence 22 nucleotides in length; (d) a mir-30 loop sequence; (e) a sense sequence wherein the sequence is complementary to the sequence of (c) except that the sequence comprises one or two mismatches relative to the sequence of (c), wherein the one or two mismatches comprise: i) a mismatch located at the position 8 to 14 of the sense sequence; or ii) a mismatch at the final 3' position (position 22) of the sense sequence; (f) a second lower stem sequence wherein the sequence is complementary to the sequence of (b), wherein the lower stem is at least 11 nucleotides in length; and (g) a second flanking sequence. In some aspects, the promoter is a eukaryotic promoter. In certain aspects, the eukaryotic promoter is a Pol II or Pol III promoter. In a specific aspect, the eukaryotic promoter is a Pol II promoter. In some aspects, the promoter is an inducible, tissue-specific-or cell lineage-specific promoter. In some aspects, the expression vector comprises 2 or more copies of the recombinant nucleic acid molecule. In some aspects, the 2 or more copies of the recombinant nucleic acid molecule form a polycistronic transcript coding sequence. In some aspects, the expression vector is a viral vector. In certain aspects, the expression vector is an adenovirus, adeno-associated virus, retrovirus, or lentivirus vector. In some aspects, the expression vector further comprises at least one drug resistance marker.

[0018] In some embodiments, the present disclosure provides a host cell comprising a recombinant nucleic acid molecule comprising a promoter element, a spacer at least 50 nucleotides in length, and at least one miRNA hairpin, the miRNA hairpin from 5' to 3' comprising in the order from (a)-(g): (a) a mir-16 flanking sequence; (b) a first lower stem sequence comprising a mir-16 sequence; (c) an anti-sense target sequence 22 nucleotides in length; (d) a mir-30 loop sequence; (e) a sense sequence wherein the sequence is complementary to the sequence of (c) except that the sequence comprises one or two mismatches relative to the sequence of (c), wherein the one or two mismatches comprise: i) a mismatch located at the position 8 to 14 of the sense sequence; or ii) a mismatch at the final 3' position (position 22) of the sense sequence; (f) a second lower stem sequence wherein the sequence is complementary to the sequence of (b), wherein the lower stem is at least 11

nucleotides in length; and (g) a second flanking sequence; or an expression vector comprising the recombinant nucleic acid molecule.

[0019] In some embodiments, the present disclosure provides a method for reducing expression of a gene in a cell comprising expressing a recombinant nucleic acid molecule comprising a promoter element, a spacer at least 50 nucleotides in length, and at least one miRNA hairpin, the miRNA hairpin from 5' to 3' comprising in the order from (a)-(g): (a) a mir-16 flanking sequence; (b) a first lower stem sequence comprising a mir-16 sequence; (c) an anti-sense target sequence 22 nucleotides in length; (d) a mir-30 loop sequence; (e) a sense sequence wherein the sequence is complementary to the sequence of (c) except that the sequence comprises one or two mismatches relative to the sequence of (c), wherein the one or two mismatches comprise: i) a mismatch located at the position 8 to 14 of the sense sequence; or ii) a mismatch at the final 3' position (position 22) of the sense sequence; (f) a second lower stem sequence wherein the sequence is complementary to the sequence of (b), wherein the lower stem is at least 11 nucleotides in length; and (g) a second flanking sequence in the cell, wherein the anti-sense target sequence (c) is complementary to the sense strand of the gene. In some aspects, expressing the nucleic acid molecule in the cell comprises transfecting the cell with the recombinant nucleic acid. In some aspects, expressing the recombinant nucleic acid molecule in the cell comprises expressing the nucleic acid molecule from an expression vector. In some aspects, the expression vector is a viral vector. In specific aspects, the expression vector is an adenovirus, adeno-associated virus, retrovirus, or lentivirus vector. In some aspects, the gene is CCR5. In some aspects, the cell is a human cell. In some aspects, the method is further defined as an *in vivo* method. In other aspects, the method is defined as an *in vitro* or *ex vivo* method. In some aspects, the method further comprises transplanting the cell expressing the recombinant nucleic acid molecule into an organism. In some aspects, the cell is comprised within an organism.

[0020] In some embodiments, the present disclosure provides a miRNA expression construct comprising a promoter sequence and at least two miRNA hairpins wherein said at least two miRNA hairpins are targeted to transcripts of immune checkpoint genes. In some aspects, the at least two miRNA hairpins target different sequences. In some aspects, the at least two miRNA hairpins target different sequences of transcripts of the same gene. In another aspect, the miRNA hairpins are targeted to different transcripts. In some aspects, the miRNA hairpins are targeted to transcripts of different genes. In some aspects, the at least two miRNA

hairpins are targeted to transcripts of at least one immune checkpoint gene selected from the group consisting of: PD1, CTLA4, LAG3, TIM3, TIGIT, CD96, BTLA, KIRs, adenosine A2a receptor, Vista, IDO, FAS, SIRP alpha, CISH, SHP-1, FOXP3, LAIR1, PVRIG, PPP2CA, PPP2CB, PTPN6, PTPN22, CD160, CRTAM, SIGLEC7, SIGLEC9, CD244, TNFRSF10B, 5 TNFRSF10A, CASP8, CASP10, CASP3, CASP6, CASP7, FADD, TGFBR2, TGFBR1, SMAD2, SMAD3, SMAD4, SMAD10, SKI, SKIL, TGIF1, IL10RA, IL10RB, HMOX2, IL6R, IL6ST, EIF2AK4, CSK, PAG1, SIT1, PRDM1, BATF, GUCY1A2, GUCY1A3, GUCY1B2, and GUCY1B3.

[0021] A miRNA expression construct in accordance with the embodiments may 10 comprise at least three miRNA hairpins. In some aspects, the at least three miRNA hairpins are each different. In some aspects, the at least three different miRNA hairpins are targeted to transcripts of at least one immune checkpoint gene. In some aspects, the at least three different miRNA hairpins are targeted to three different immune checkpoint genes. In some aspects, the miRNA expression construct comprises at least 4, 5, 6, 7, 8, 9 or 10 miRNA hairpins. In some 15 aspects, the at least 4, 5, 6, 7, 8, 9 or 10 miRNA hairpins are each different. In some aspects, the at least 4, 5, 6, 7, 8, 9 or 10 miRNA hairpins are targeted to transcripts of 2, 3, 4 or 5 different immune checkpoint genes.

[0022] In some embodiments, the miRNA expression construct may comprise a spacer 20 sequence positioned between the promoter and the at least two miRNA hairpins. In some aspects, the spacer is between 50 and 1,000 nucleotides in length.

[0023] In some aspects, the promoter sequence of the miRNA expression construct is at least 80% identical to the EF1s promoter sequence. In some aspects, the promoter sequence is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the EF1s promoter sequence. In some aspects, the 25 promoter sequence is identical to the EF1s promoter sequence.

[0024] In some aspects, the promoter sequence of the miRNA expression construct is at least 80% identical to the UBI promoter sequence. In some aspects, the promoter sequence is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the UBI promoter sequence. In some aspects, the 30 promoter sequence is identical to the UBI promoter sequence.

[0025] A miRNA expression construct in accordance with the embodiments may further comprise a receptor sequence. In some aspects, the receptor sequence is a chimeric antigen receptor. In some aspects, the receptor sequence is a T cell receptor sequence.

5 [0026] A miRNA expression construct in accordance with the embodiments may further comprise a selective marker. In some aspects, the selective marker is a selection gene. In some aspects, the selection gene is LNGFR or a derivative thereof. In some aspects, the miRNA expression construct further comprises a suicide gene. For example, the suicide gene can be herpes simplex virus thymidine kinase (HSV-tk), inducible caspase 9 (iCasp9), truncated endothelial growth factor receptor (tEGFR), RQR8, dihydrofolate reductase (DHFR),
10 or thymidylate synthase (TYMS).

[0027] A miRNA expression construct in accordance with the embodiments may comprise a peptide cleavage site. In some aspects, the peptide cleavage site is a 2A peptide. In some aspects, the 2A peptide is selected from the group comprising: 2A, P2A, T2A, E2A, F2A, BmCPV 2A, and BmIFV 2A. In specific aspects, the 2A peptide is T2A.

15 [0028] In some embodiments, the present disclosure provides a vector comprising a miRNA expression construct comprising a promoter sequence and at least two miRNA hairpins wherein said at least two miRNA hairpins are targeted to transcripts of immune checkpoint genes. In some aspects, the vector is a viral vector. In some aspects, the viral vector is an adenovirus, adeno-associated virus, retrovirus, or lentiviral vector.

20 [0029] In some embodiments, the present disclosure provides a mammalian cell comprising a miRNA expression construct comprising a promoter sequence and at least two miRNA hairpins wherein said at least two miRNA hairpins are targeted to transcripts of immune checkpoint genes, or a vector comprising said miRNA expression construct. In some aspects, the mammalian cell is an immune effector cell. In some aspects, the immune effector
25 cell is selected from the group comprising: T cells, TILS, TCR-engineered T cells, CAR T cells, NK cells, NK/T cells, and T regulatory cells.

[0030] In some embodiments, there is provided a method for preparing engineered immune effector cells comprising transfecting or transducing the immune effector cells with the miRNA expression construct in accordance with the embodiments or transducing the
30 immune effector cells with a vector comprising an miRNA expression construct in accordance with the embodiments. In some aspects, the method for preparing engineered immune effector

cells comprises transfecting or transducing a chimeric antigen receptor sequence or T cell receptor sequence into immune effector cells and then transfecting or transducing the miRNA expression construct of the embodiments or the vector comprising a miRNA expression construct of the embodiments into the cells.

5 **[0031]** In some embodiments, there is provided a method for preparing engineered immune effector cells from a patient. In some aspects, the method for preparing engineered immune effector cells from a patient comprises: (a) collecting immune effector cells from the patient; and (b) transfecting the immune effector cells with a miRNA expression construct of the embodiments or transducing the immune effector cells with a vector comprising a miRNA
10 expression construct to generate engineered immune effector cells. In some aspects, the method for preparing engineered immune cells from a patient comprises: (a) collecting immune effector cells from the patient; (b) transducing or transfecting the immune effector cells with a chimeric antigen receptor or T cell receptor to generate a modified immune effector cells; and (c) transducing or transfecting the modified immune effector cells with a miRNA expression
15 construct in accordance with the embodiments, or a vector comprising a miRNA expression construct in accordance with the embodiments, to generate engineered immune effector cells. In still further aspects, an immune effector cell of the embodiments is a T cell, a NK cell or a NK/T cell. In some aspects, the immune effector cell further expresses an recombinant T cell receptor or a chimeric antigen receptor (CAR).

20 **[0032]** In some embodiments, there is provided a method for treating a patient in need thereof, comprising introducing engineered immune effector cells in accordance with the embodiments into the patient. For example, in some aspects, the patient is a patient with cancer.

[0033] In a further embodiment there is provided an immune effector cell comprising one or more miRNA expression constructs that target a CCR5 and an immune checkpoint
25 inhibitor gene. For example, the checkpoint inhibitor gene can be PD1, CTLA4, LAG3, TIM3, TIGIT, CD96, BTLA, KIRs, adenosine A2a receptor, ARG2 (arginase 2), Vista, IDO, FAS, SIRP alpha, CISH, SHP-1, FOXP3, LAIR1, PVRIG, PPP2CA, PPP2CB, PTPN6, PTPN22, CD160, CRTAM, SIGLEC7, SIGLEC9, CD244, TNFRSF10B, TNFRSF10A, CASP8, CASP10, CASP3, CASP6, CASP7, FADD, TGFBR2, TGFBR1, SMAD2, SMAD3,
30 SMAD4, SMAD10, SKI, SKIL, TGIF1, IL10RA, IL10RB, HMOX2, IL6R, IL6ST, EIF2AK4, CSK, PAG1, SIT1, PRDM1, BATF, GUCY1A2, GUCY1A3, GUCY1B2, or GUCY1B3. In some aspects, the checkpoint inhibitor gene is PD1. In some aspects, the PD1 target sequence

is SEQ ID NO: 59, 60 or 61, preferably SEQ ID NO: 59. In some aspects, the immune effector cell is selected from the group consisting of: T cells, TILS, TCR-engineered T cells, CAR T cells, NK cells, NK/T cells, T regulatory cells, monocytes and macrophages. For instance, the cell can be a T cell, such as a CAR T-cell. In some aspects, the cell comprises a CAR that
5 targeted HIV infected cells. In further aspects, a cell comprises one or more miRNA expression constructs that target a CCR5 and at least two immune checkpoint inhibitor genes. Thus, a cell can comprise any of the miRNA expression constructs of the embodiments.

[0034] In still a further embodiment there is provided an expression construct comprising a miRNA sequence that target a CCR5 and an immune checkpoint inhibitor gene.
10 For example, the miRNA sequence can be a sequence in accordance with any of the embodiments described herein. In some aspects, the construct further comprises a CAR expression sequence, such as a CAR sequence that targets HIV infected cells.

[0035] As used herein, “essentially free,” in terms of a specified component, is used herein to mean that none of the specified component has been purposefully formulated into a
15 composition and/or is present only as a contaminant or in trace amounts. The total amount of the specified component resulting from any unintended contamination of a composition is preferably below 0.01%. Most preferred is a composition in which no amount of the specified component can be detected with standard analytical methods.

[0036] As used herein in the specification and claims, “a” or “an” may mean one or
20 more. As used herein in the specification and claims, when used in conjunction with the word “comprising”, the words “a” or “an” may mean one or more than one. As used herein, in the specification and claim, “another” or “a further” may mean at least a second or more.

[0037] As used herein in the specification and claims, the term “about” is used to
25 indicate that a value includes the inherent variation of error for the device, the method being employed to determine the value, or the variation that exists among the study subjects.

[0038] Other objects, features and advantages of the present invention will become
apparent from the following detailed description. It should be understood, however, that the
detailed description and the specific examples, while indicating certain embodiments of the
invention, are given by way of illustration only, since various changes and modifications within
30 the spirit and scope of the invention will become apparent to those skilled in the art from this
detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

[0039] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

[0040] **FIG. 1: A spacer sequence is required for polymerase II promoter driven miRNA knock down.** (a) Schematic representation of the miRGE-based used in this experiment. All hairpins were designed to target CCR5. Two different pol II dependent promoters (Ubiquitin C and Elongation Factor 1 short) drive miRGE expression (single or triple hairpin) with or without the GFP sequence as spacer. The position of the spacer, either in 5' or in 3' of the promoter was also investigated. (b) Constructs expressed with a Ubiquitin C promoter or Elongation Factor 1 short promoter were transduced at 0.2 multiplicity of infection (MOI) in HeLa cells expressing CCR5. Flow cytometry determination of CCR5 expression in the transduced population (mCherry +) versus the untransduced population (mCherry-): WT HeLa cells (double negative), HeLa R5 cells (CCR5 positive). R5 + Ctrl mCherry vector; R5 + single mirGE hairpin) with GFP spacer. (b') Mean APC fluorescence values in the transduced (red) and untransduced (blue) populations were used to calculate the miRNA-mediated CCR5 knock-down. (c) Bar graph showing the relative expression of CCR5 with the UBI promoter constructs. (d) Histogram showing the relative expression of CCR5 with the EF1 short promoter constructs. (e) Concatenation efficiency (E) of the different constructs as calculated on the bar graph. If E=1 absence of additive effect is observed with the concatemered hairpins (efficiency is 0%). If E=3 perfect additive effect of the hairpin is observed in the concatenate (efficiency is 100%). Data represent the mean +/- SEM of three independent experiments.

[0041] **FIG. 2: Efficiency of the miRNA-based knockdown depends on the spacer.** (a) Single miRGE hairpin-based constructs targeting CCR5 were designed with different spacers derived either from coding sequences of GFP (Green Fluorescent Protein), MGST-2 (Microsomal Glutathione S-transferase-2), dNGFR (truncated Nerve Growth Factor Receptor), HO-1 (Heme oxygenase-1), HO-1, and H2B (Histone 2B) or from noncoding sequences (first intron of the CD4 gene = iCD41) and transduced at 0.2 MOI in HeLa R5 cells. Histogram showing the expression of CCR5 in the transduced population relative to the untransduced population, as assessed by FACS immunostaining. (b) miRGE constructs were designed with

truncated forms of GFP (GFP1 and GFP2) or (c) the first intron of CD4 (iCD42 and iCD43) and transduced at 0.2 MOI in HeLa R5 cells. Histograms show the level of CCR5 expression of the transduced population relatively to the untransduced population. Data represent the mean +/- SEM of three independent experiments.

5 **[0042] FIG. 3: The spacer sequence determines the additive effects of miRNA hairpin concatenation.** (a) The efficiency of MGST2, H2B and GFP as spacer was assessed on miRGE hairpin concatenation (three hairpins concatenate) in HeLa expressing CCR5 cells. (b) Histogram shows the level of CCR5 expression of the transduced population relatively to the remained untransduced population for the GFP spacer (black bars), the second part of GFP
10 (GFP2) (hatched), MGST2 spacer (dark grey bars) and the H2B spacer (clear grey bars). (c) The bar graph shows the concatenation efficiency for the triple hairpin constructs, as calculated with the formula in Fig. 9. For the calculation of the concatenation efficiency, CCR5 knockdown with a single miRGE hairpin (knock-down potency (KP)) and with a triple miRGE concatenate (concatenation potency (CP)) were considered. (d-e) The potency of MGST2 and
15 GFP as spacers was also compared in a triple hairpin concatenate targeting the NADPH oxidase subunit p22^{phox}. mRNA level of p22^{phox} as assessed in the promyelocytic leukemia cell line PLB985 by QPCR (d) and on NADPH oxidase activity by Amplex red assay (e). Data represent the mean +/- SEM of three independent experiments.

[0043] FIG.4: Translation-independent activity of the GFP spacer in cell lines and
20 **tissue explants.** (a) Design of the stopGFP spacer, harboring stop codons in all possible reading frames of the GFP cDNA in 3' of the initiation codon (ATG). (b) HeLa R5 Cells were transduced at >1 MOI with both coding and noncoding forms of GFP. FACS histograms show the fluorescence of GFP in transduced cells. The GFP fluorescence of cells transduced with the stopGFP construct was comparable to the control (non-transduced HeLa cells). (c) The spacer
25 activity of stopGFP sequence was also assessed by FACS on CCR5 expression after 0.2 MOI transduction in HeLa R5 cells. The histogram shows the expression of CCR5 of the transduced population relatively to the untransduced population as assessed by FACS immunostaining. Data represent the mean +/- SEM of three independent experiments. (d) Organotypic culture of newborn rat cochlear explants transduced with increasing amounts stopGFP triple miRGE
30 hairpin concatenate targeting p22^{phox} (10⁶ to 10⁷ vector particles). Hair cells are stained for myosin 7a (in green) and efficiently transduced cells express the marker gene mCherry (red).

After five days in vitro, expression of the viral gene GAG (e) and p22^{phox} (f) was assessed by qPCR. TU = transducing units.

[0044] FIG. 5: The spacer sequence regulates the steady state levels, but not the half-life of miRGE. HeLa expressing CCR5 were transduced with single hairpin vector with GFP, LNGFR, MGST2 or iCD41 as spacers. (a) Unprocessed (pri-miRGE) or (e) mature miRGE level was assessed by qPCR using primers matching the flanking region of pri-miRGE (F1-R1) or the targeting strand of the mature miRGE (F2-R2). (b) Representative qPCR amplification plot of unprocessed miRGE level with GFP, NGFR and MGST2 as spacers. Note that without spacer or with iCD41 as spacer, miRGE level was below detection threshold. GAPDH was used as housekeeping gene. ΔR_n of 0.2 was defined as the threshold (red line). (c) Bar graph shows the relative level of unprocessed miRGE as averaged from three independent experiments. The highest value of miRGE expression, normalized to 1.0 corresponds to a Ct value of 28.1 ± 0.3 . BT= below detection threshold. (d) Transcription was blocked with Actinomycin D at different time point (0 – 240 min) and effect of the spacer was assessed on unprocessed miRGE half-life. Graph shows the relative miRGE decay over time and half-life for each spacer is displayed in the table. (f and g) Comparison of the steady state level of the mature miRGE as assessed by qPCR from HeLa cells transduced with single hairpin (f) or triple hairpin concatenates (g) with different spacers. Data represent the mean +/- SEM of three independent experiments.

[0045] FIG. 6: Maximizing concatenation and achieving multi-target knock-down. (a) Efficiency of the stopGFP triple concatenate targeting CCR5 (mirGE 7-7-7) was compared to constructs harboring a fourth or a fifth hairpin either targeting CCR5 or a second target – GFP. Bar graphs show the steady state level of the mature miRGE targeting CCR5 (7) (b) or targeting GFP (G) (d), as assessed by qPCR and the ability of these constructs to knockdown CCR5 expression (c) or GFP expression (e) in HeLa cells. Vector expressing a single miRGE hairpin targeting CCR5 or GFP were used as controls. (f) When replacing the stopGFP with MGST2 as spacer, activity of the fourth and the fifth hairpin was decreased, as compared to the single miRGE hairpin control (miRGFP) or to the fifth hairpin of the stopGFP construct. Data represent the mean +/- SEM of three independent experiments.

[0046] FIG. 7: Impact of the length and biophysical features of the spacer on the knockdown efficiency. Plots showing the correlation between CCR5 knockdown and (a) the minimum free energy/length or (b) the GC content of the spacers described in this figure.

[0047] FIG. 8: Overall strategy for the design of efficient miRGE concatenate targeting NOX3 activity. (a) Candidate siRNA sequences are design of in silico and selected on their ability to knock-down the target mRNA (NOX3, p22^{phox} or NOXO1). The most active siRNA sequence is then cloned in the miRGE backbone to construct the SMIG. Validation of the SMIG efficiency is verified on the same target expressing cell line. (b) Potency of 8 siRNA candidates, targeting mRNA encoding for the NOX3 complex (NOX3, p22^{phox} and NoxO1) were assessed with respect to NOX3 activity by the amplex red method. (c) Effect of the most efficient sequence (targeting p22^{phox}) on NOX activity was verified by Western Blot. (d-e) Efficiency of the triple hairpin concatenate SMIG designed with the most active siRNA sequence was checked on the NOX3 expressing cell line either by QPCR (d) or by measurement of the production of ROS (e).

[0048] FIG. 9: Calculation of the efficiency of concatenation of the miRGE hairpins. (a) Table showing the formula allowing the calculation of the efficiency of concatenation (E) for GFP, MGST2 and H2B spacers. For the calculation of the concatenation efficiency, CCR5 knockdown with a single miRGE hairpin (knock-down potency (KP)) and with triple miRGE concatenate (concatenation potency (CP)) were considered. (b) Table summarizing the knock-down potency (KP), the concatenation efficiency (E) and their product, the general vector efficiency. (c) The former one is also displayed on the histogram.

[0049] FIG. 10: Schematic of prophetic synthetic minigene to generate re-directed immunotherapeutic cells with intrinsic immune checkpoint knockdown. Promoter selected to allow tissue specific expression, while the spacer sequence and length is optimized to allow expression of all miRNA hairpins. The miRNA hairpins may target a specific gene or gene(s) of interest while the CAR or TCR sequences allow the targeting of immunotherapeutic cells to specific antigens. T2A is a cleavage peptide site, and LNGFR allows for selection of engineered cells, while suicide genes would enable rapid removal of cells in case of toxicity.

[0050] FIG. 11: Optimized minigene architecture allows sustained *in vivo* knockdown of CCR5 in circulating cells. (A) Six NGS newborn mice were engrafted with 260,000 human CD34+ hematopoietic stem cells (HSCs), following transduction with triple hairpin concatenate targeting CCR5. At the age of 28 weeks, blood was harvested for analysis of CCR5 expression. (B) FACS plots showing CD4+ T cells from mice transplanted with non-transduced HSC (left) or transplanted with stop GFP- 777 transduced HSC (center). Right plot shows CD4+ T cells stained with irrelevant antibody (untransduced HSC). mCherry+ cells

indicate effectively transduced cells. (C) Histogram showing expression level of CCR5 in transduced (mCherry+) and remaining untransduced (mCherry-) CD4 T cell population for a single transplanted mouse, relative to irrelevant antibody (isotype). Cells on the right of the dotted line represent high CCR5- expressing CD4 T cells. (D) Comparison of the CCR5 expression level in high CCR5 CD4+ T cells population in five engrafted mice. Untransduced ctrl stands for mice engrafted with non-transduced human CD34+ cells (n = 3).

[0051] FIG. 12: Engraftment rate of human hematopoietic stem cells in NOD/SCID mice, 23 weeks following transplantation. FACS plot showing human circulating leukocytes expressing human CD45 marker in (a) a mouse transplanted with untransduced HSC or (b) the 6 mice transplanted with HSC transduced with the triple hairpin concatenate targeting CCR5. Engraftment rate is between 12.4% and 44%.

[0052] FIG. 13: Identification of human CD4+ T cells from the transplanted mice blood. Total lymphocytes were selected according to their FSC/SSC coordinates (a). Following doublet elimination (b), human leukocytes were selected with human CD45 staining (c), then human lymphocytes with human CD3 antibody (d). Finally, CD4+ T cells were discriminated from CD8+ T cells with human CD4 and human CD8 antibodies (e).

[0053] FIG. 14: Efficiency in CCR5 downregulation using 1-3 hairpin mirGE constructs against CCR5. (A) Architecture of therapeutic minigenes showing 1-3 hairpins, with each being identical and targeting CCR5; (B) Aligned flow cytometric histograms demonstrating the decrease in fluorescent intensity within transduced HeLaR5 cells (mCherry positive populations); (C) Relative CCR5 expression levels when compared to HeLaR5 cells transduced with mCherry only control vector (n=3).

[0054] FIG. 15: Identification of the optimal target sequence for PD1 downregulation. Three PD1 target sequences, identified based on in silico design, were used for construction of single hairpin mirGE therapeutic minigenes and packaged into lentiviral vectors for transduction of primary T cells according to the experimental plan shown in (A); (B-C) Flow cytometry dot plots and histograms indicating the PD1-1A construct to be most effective at decreasing PD1 expression in transduced T cell populations (mCherry+); (D-E) Bar graphs illustrating a relative reduction in PD1 expressing cells and expression levels (n=4).

[0055] FIG. 16: PD1 downregulation with 1 to 3 hairpin mirGE therapeutic minigenes. After having identified a target sequence accessible for mirGE downregulation of

PD1, two and three hairpin minigenes (same hairpin sequence) were constructed. The constructs were then packaged into lentiviral vectors for transduction of primary T cells from healthy donors (A); (B-C) Flow cytometry dot plots and histograms illustrating an increased knockdown of PD1 with 2 and 3 hairpin constructs when compared to the 1 hairpin construct.;
5 (D-E) Bar graphs illustrating the relative reduction in PD1 expressing cells and PD1 expression levels (n=3), indicating equivalent knockdown of PD1 using 2 and 3 hairpin constructs.

[0056] FIG. 17: Efficiency in CCR5 downregulation using mirGE constructs with two CCR5-targeting hairpins in terminal positions. (A) Architecture of therapeutic minigenes showing the position CCR5-targeting hairpins relative to PD1 and GFP-targeting hairpins;
10 (B) Aligned flow cytometric histograms demonstrating a decrease in fluorescent intensity within transduced HeLaR5 cells (mCherry positive populations); (C) Relative CCR5 expression levels when compared to HeLaR5 cells transduced with mCherry only control vector (n=3 to 5).

[0057] FIG. 18: Effect of PD1 knockdown in anti-cKit CAR T cells after a four day co-culture with HL-60 target cells. (A) Transduction rate of anti-cKit CAR T cells with a PD1 targeting mirGE (3 hairpin), based on mCherry positivity; (B) Increase in mirGE expressing CAR T cells on Day 4, based on mCherry expression; (C) Absolute cell numbers of anti-cKit CAR T cells after a four day co-culture with HL-60 target cells; (D) Fold increase of CAR T cells on over the four day co-culture period (starting with 100,000 CAR T cells on
15 Day 1); (E-F) Flow cytometric dot plots, overlays and histograms of CAR T cells after the four day co-culture period; (G) Percentage of PD1-expressing CAR T cells.
20

[0058] FIG. 19: Knockdown of CCR5 and PD1 in primary T cells. (A-B) Flow cytometric dot plots, overlays and histograms illustrating knockdown of both CCR5 and PD1 independently in primary T cells transduced with a 4 hairpin mirGE construct (two hairpins against PD1, followed by two hairpins against CCR5) and control vector (mCherry only); (C)
25 Overlaid dot plots of CCR5 vs PD1 populations, gated on untransduced (mCherry negative) and 4 hairpin transduced (mCherry positive) T cell populations.

DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

I. The Present Embodiments

[0059] The present invention relates generally to miRNA expression constructs. The present invention relates to constructs for the expression of multiple miRNAs. The present invention further relates to the use of a spacer sequence between the promoter and the miRNA sequences. In some aspects, the spacer sequence may be from GFP.

II. RNA inhibition

[0060] An inhibitory nucleic acid may inhibit the transcription of a gene or prevent the translation of a gene transcript in a cell. An inhibitory nucleic acid may be from 16 to 1000 nucleotides long, and in certain embodiments from 18 to 100 nucleotides long. In certain embodiments, the inhibitory nucleic acid is an isolated nucleic acid that binds or hybridizes to a gene of interest.

[0061] Inhibitory nucleic acids are well known in the art. For example, siRNA, shRNA and double-stranded RNA have been described in U.S. Patents 6,506,559 and 6,573,099, as well as in U.S. Patent Publications 2003/0051263, 2003/0055020, 2004/0265839, 2002/0168707, 2003/0159161, and 2004/0064842, all of which are herein incorporated by reference in their entirety.

[0062] Since the discovery of RNAi by Fire and colleagues in 1998, the biochemical mechanisms have been rapidly characterized. Double stranded RNA (dsRNA) is cleaved by Dicer, which is an RNAase III family ribonuclease. This process yields miRNAs of ~21 nucleotides in length. These miRNAs are incorporated into a multiprotein RNA-induced silencing complex (RISC) that is guided to target mRNA. RISC cleaves the target mRNA in the middle of the complementary region. In mammalian cells, the related miRNAs are found that are short RNA fragments (~22 nucleotides). miRNAs are generated after Dicer-mediated cleavage of longer (~70 nucleotide) precursors with imperfect hairpin RNA structures. The miRNA is incorporated into a miRNA-protein complex (miRNP), which leads to translational repression of target mRNA.

[0063] In designing RNAi there are several factors that need to be considered such as the nature of the siRNA, the durability of the silencing effect, and the choice of delivery system. To produce an RNAi effect, the miRNA that is introduced into the organism will typically

contain exonic sequences. Furthermore, the RNAi process is homology dependent, so the sequences must be carefully selected so as to maximize gene specificity, while minimizing the possibility of cross-interference between homologous, but not gene-specific sequences. Particularly the miRNA exhibits greater than 80, 85, 90, 95, 98% or even 100% identity
5 between the sequence of the miRNA and a portion of the nucleotide sequence of a target gene. Sequences less than about 80% identical to the target gene are substantially less effective. Thus, the greater identity between the miRNA and the target gene to be inhibited, the less likely expression of unrelated genes will be affected.

[0064] In addition, the size of the miRNA is an important consideration. In some
10 embodiments, the present invention relates to miRNA molecules that include at least about 19-25 nucleotides, and are able to modulate target gene expression. In the context of the present invention, the miRNA is particularly less than 500, 200, 100, 50, 25, 24, 23 or 22 nucleotides in length. In some embodiments, the miRNA is from about 25 nucleotides to about 35 nucleotides or from about 19 nucleotides to about 25 nucleotides in length.

[0065] To improve the effectiveness of miRNA-mediated gene silencing, guidelines
15 for selection of target sites on mRNA have been developed for optimal design of miRNA (Soutschek et al., 2004; Wadhwa et al., 2004). These strategies may allow for rational approaches for selecting siRNA sequences to achieve maximal gene knockdown. To facilitate the entry of miRNA into cells and tissues, a variety of vectors including plasmids and viral
20 vectors such as adenovirus, lentivirus, and retrovirus have been used (Wadhwa et al., 2004).

[0066] Within an inhibitory nucleic acid, the components of a nucleic acid need not be
of the same type or homogenous throughout (e.g., an inhibitory nucleic acid may comprise a nucleotide and a nucleic acid or nucleotide analog). Typically, an inhibitory nucleic acid form a double-stranded structure; the double-stranded structure may result from two separate nucleic
25 acids that are partially or completely complementary. In certain embodiments of the present invention, the inhibitory nucleic acid may comprise only a single nucleic acid (polynucleotide) or nucleic acid analog and form a double-stranded structure by complementing with itself (e.g., forming a hairpin loop). The double-stranded structure of the inhibitory nucleic acid may comprise 16 - 500 or more contiguous nucleobases, including all ranges therebetween. The
30 inhibitory nucleic acid may comprise 17 to 35 contiguous nucleobases, more particularly 18 to 30 contiguous nucleobases, more particularly 19 to 25 nucleobases, more particularly 20 to 23 contiguous nucleobases, or 20 to 22 contiguous nucleobases, or 21 contiguous nucleobases that

hybridize with a complementary nucleic acid (which may be another part of the same nucleic acid or a separate complementary nucleic acid) to form a double-stranded structure.

[0067] miRNA can be obtained from commercial sources, natural sources, or can be synthesized using any of a number of techniques well-known to those of ordinary skill in the art. For example, commercial sources of predesigned miRNA include Invitrogen's Stealth™ Select technology (Carlsbad, CA), Ambion® (Austin, TX), and Qiagen® (Valencia, CA). An inhibitory nucleic acid that can be applied in the compositions and methods of the present invention may be any nucleic acid sequence that has been found by any source to be a validated downregulator of a target gene.

10 [0068] In some embodiments, the miRNA molecule is at least 75, 80, 85, or 90% homologous, particularly at least 95%, 99%, or 100% similar or identical, or any percentages in between the foregoing (e.g., the invention contemplates 75% and greater, 80% and greater, 85% and greater, and so on, and said ranges are intended to include all whole numbers in between), to at least 10 contiguous nucleotides of any of the nucleic acid sequences encoding
15 a full-length protein.

[0069] The miRNA may also comprise an alteration of one or more nucleotides. Such alterations can include the addition of non-nucleotide material, such as to the end(s) of the 19 to 25 nucleotide RNA or internally (at one or more nucleotides of the RNA). In certain aspects, the RNA molecule contains a 3'-hydroxyl group. Nucleotides in the RNA molecules of the present invention can also comprise non-standard nucleotides, including non-naturally occurring nucleotides or deoxyribonucleotides. The double-stranded oligonucleotide may contain a modified backbone, for example, phosphorothioate, phosphorodithioate, or other modified backbones known in the art, or may contain non-natural internucleoside linkages. Additional modifications of siRNAs (e.g., 2'-O-methyl ribonucleotides, 2'-deoxy-2'-fluoro ribonucleotides, "universal base" nucleotides, 5-C-methyl nucleotides, one or more phosphorothioate internucleotide linkages, and inverted deoxyabasic residue incorporation) can be found in U.S. Publication 2004/0019001 and U.S. Patent 6,673,611 (each of which is incorporated by reference in its entirety). Collectively, all such altered nucleic acids or RNAs described above are referred to as modified miRNAs.

II. Vectors for Cloning, Gene Transfer and Expression

[0070] Within certain aspects expression vectors are employed to express a nucleic acid of interest, such as a nucleic acid that inhibits the expression of a particular gene. Expression requires that appropriate signals be provided in the vectors, and which include various regulatory elements, such as enhancers/promoters from both viral and mammalian sources that drive expression of the genes of interest in host cells. Elements designed to optimize RNA stability in host cells also are defined. The conditions for the use of a number of dominant drug selection markers for establishing permanent, stable cell clones expressing the products are also provided, as is an element that links expression of the drug selection markers to expression of the polypeptide.

A. Regulatory Elements

[0071] Throughout this application, the term “expression construct” or “expression vector” is meant to include any type of genetic construct containing a nucleic acid coding for a gene product in which part or all of the nucleic acid encoding sequence is capable of being transcribed. The transcript may be translated into a protein, but it need not be. In certain embodiments, expression includes both transcription of a gene and translation of mRNA into a gene product. In other embodiments, expression only includes transcription of the nucleic acid encoding a gene of interest *i.e.*, as is the case with RNA molecules of the embodiments.

[0072] In certain embodiments, the nucleic acid encoding a gene product is under transcriptional control of a promoter. A “promoter” refers to a DNA sequence recognized by the synthetic machinery of the cell, or introduced synthetic machinery, required to initiate the specific transcription of a gene. The phrase “under transcriptional control” means that the promoter is in the correct location and orientation in relation to the nucleic acid to control RNA polymerase initiation and expression of the gene.

[0073] The term promoter will be used here to refer to a group of transcriptional control modules that are clustered around the initiation site for eukaryotic RNA polymerase (Pol) I, II or III. Much of the thinking about how promoters are organized derives from analyses of several viral Pol II promoters, including those for the HSV thymidine kinase (*tk*) and SV40 early transcription units. These studies, augmented by more recent work, have shown that promoters are composed of discrete functional modules, each consisting of

approximately 7-20 bp of DNA, and containing one or more recognition sites for transcriptional activator or repressor proteins.

[0074] At least one module in each promoter functions to position the start site for RNA synthesis. The best known example of this is the TATA box, but in some promoters
5 lacking a TATA box, such as the promoter for the mammalian terminal deoxynucleotidyl transferase gene and the promoter for the SV40 late genes, a discrete element overlying the start site itself helps to fix the place of initiation.

[0075] Additional promoter elements regulate the frequency of transcriptional initiation. Typically, these are located in the region 30-110 bp upstream of the start site,
10 although a number of promoters have recently been shown to contain functional elements downstream of the start site as well. The spacing between promoter elements frequently is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another. In the tk promoter, the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline. Depending on the promoter, it appears that
15 individual elements can function either co-operatively or independently to activate transcription.

[0076] In some embodiments, the promoter comprises an Elongation Factor 1 short (EF1s) promoter. In other embodiments, the human cytomegalovirus (CMV) immediate early gene promoter, the SV40 early promoter, the Rous sarcoma virus long terminal repeat,
20 rat insulin promoter and glyceraldehyde-3-phosphate dehydrogenase can be used to obtain high-level expression of the coding sequence of interest. The use of other viral or mammalian cellular or bacterial phage promoters which are well-known in the art to achieve expression of a coding sequence of interest is contemplated as well, provided that the levels of expression are sufficient for a given purpose.

[0077] By employing a promoter with well-known properties, the level and
25 pattern of expression of the protein of interest following transfection or transformation can be optimized. Further, selection of a promoter that is regulated in response to specific physiologic signals can permit inducible expression of the gene product. Tables 1 and 2 list several regulatory elements that may be employed, in the context of the present invention, to regulate
30 the expression of the gene of interest. This list is not intended to be exhaustive of all the possible elements involved in the promotion of gene expression but, merely, to be exemplary

thereof. In some aspects, a promoter for use according to the instant embodiments is a non-tissue specific promoter, such as a constitutive promoter.

[0078] Enhancers are genetic elements that increase transcription from a promoter located at a distant position on the same molecule of DNA. Enhancers are organized
5 much like promoters. That is, they are composed of many individual elements, each of which binds to one or more transcriptional proteins.

[0079] The basic distinction between enhancers and promoters is operational. An enhancer region as a whole must be able to stimulate transcription at a distance; this need not be true of a promoter region or its component elements. On the other hand, a promoter
10 must have one or more elements that direct initiation of RNA synthesis at a particular site and in a particular orientation, whereas enhancers lack these specificities. Promoters and enhancers are often overlapping and contiguous, often seeming to have a very similar modular organization.

[0080] Below is a list of viral promoters, cellular promoters/enhancers and
15 inducible promoters/enhancers that could be used in combination with the nucleic acid encoding a gene or miRNA of interest in an expression construct (Table 1 and Table 2). Additionally, any promoter/enhancer combination (as per the Eukaryotic Promoter Data Base EPDB) could also be used to drive expression of the gene or miRNA of interest. Truncated promoters may also be used to drive expression. Eukaryotic cells can support cytoplasmic
20 transcription from certain bacterial promoters if the appropriate bacterial polymerase is provided, either as part of the delivery complex or as an additional genetic expression construct.

TABLE 1	
Promoter and/or Enhancer	
Promoter/Enhancer	References
Elongation Factor 1 alpha (EF1 α)	Kim <i>et al.</i> , 1990
Immunoglobulin Heavy Chain	Banerji <i>et al.</i> , 1983; Gilles <i>et al.</i> , 1983; Grosschedl <i>et al.</i> , 1985; Atchinson <i>et al.</i> , 1986, 1987; Imler <i>et al.</i> , 1987; Weinberger <i>et al.</i> , 1984; Kiledjian <i>et al.</i> , 1988; Porton <i>et al.</i> ; 1990
Immunoglobulin Light Chain	Queen <i>et al.</i> , 1983; Picard <i>et al.</i> , 1984

TABLE 1	
Promoter and/or Enhancer	
Promoter/Enhancer	References
T-Cell Receptor	Luria <i>et al.</i> , 1987; Winoto <i>et al.</i> , 1989; Redondo <i>et al.</i> ; 1990
HLA DQ a and/or DQ β	Sullivan <i>et al.</i> , 1987
β -Interferon	Goodbourn <i>et al.</i> , 1986; Fujita <i>et al.</i> , 1987; Goodbourn <i>et al.</i> , 1988
Interleukin-2	Greene <i>et al.</i> , 1989
Interleukin-2 Receptor	Greene <i>et al.</i> , 1989; Lin <i>et al.</i> , 1990
MHC Class II 5	Koch <i>et al.</i> , 1989
MHC Class II HLA-DRa	Sherman <i>et al.</i> , 1989
β -Actin	Kawamoto <i>et al.</i> , 1988; Ng <i>et al.</i> ; 1989
Muscle Creatine Kinase (MCK)	Jaynes <i>et al.</i> , 1988; Horlick <i>et al.</i> , 1989; Johnson <i>et al.</i> , 1989
Prealbumin (Transthyretin)	Costa <i>et al.</i> , 1988
Elastase I	Ornitz <i>et al.</i> , 1987
Metallothionein (MTII)	Karin <i>et al.</i> , 1987; Culotta <i>et al.</i> , 1989
Collagenase	Pinkert <i>et al.</i> , 1987; Angel <i>et al.</i> , 1987a
Albumin	Pinkert <i>et al.</i> , 1987; Tronche <i>et al.</i> , 1989, 1990
α -Fetoprotein	Godbout <i>et al.</i> , 1988; Campere <i>et al.</i> , 1989
t-Globin	Bodine <i>et al.</i> , 1987; Perez-Stable <i>et al.</i> , 1990
β -Globin	Trudel <i>et al.</i> , 1987
c-fos	Cohen <i>et al.</i> , 1987
c-HA- <i>ras</i>	Triesman, 1986; Deschamps <i>et al.</i> , 1985
Insulin	Edlund <i>et al.</i> , 1985
Neural Cell Adhesion Molecule (NCAM)	Hirsh <i>et al.</i> , 1990
α_1 -Antitrypsin	Latimer <i>et al.</i> , 1990
H2B (TH2B) Histone	Hwang <i>et al.</i> , 1990
Mouse and/or Type I Collagen	Ripe <i>et al.</i> , 1989
Glucose-Regulated Proteins (GRP94 and GRP78)	Chang <i>et al.</i> , 1989
Rat Growth Hormone	Larsen <i>et al.</i> , 1986

TABLE 1	
Promoter and/or Enhancer	
Promoter/Enhancer	References
Human Serum Amyloid A (SAA)	Edbrooke <i>et al.</i> , 1989
Troponin I (TN I)	Yutzey <i>et al.</i> , 1989
Platelet-Derived Growth Factor (PDGF)	Pech <i>et al.</i> , 1989
Duchenne Muscular Dystrophy	Klamut <i>et al.</i> , 1990
SV40	Banerji <i>et al.</i> , 1981; Moreau <i>et al.</i> , 1981; Sleight <i>et al.</i> , 1985; Firak <i>et al.</i> , 1986; Herr <i>et al.</i> , 1986; Imbra <i>et al.</i> , 1986; Kadesch <i>et al.</i> , 1986; Wang <i>et al.</i> , 1986; Ondek <i>et al.</i> , 1987; Kuhl <i>et al.</i> , 1987; Schaffner <i>et al.</i> , 1988
Polyoma	Swartzendruber <i>et al.</i> , 1975; Vasseur <i>et al.</i> , 1980; Katinka <i>et al.</i> , 1980, 1981; Tyndell <i>et al.</i> , 1981; Dandolo <i>et al.</i> , 1983; de Villiers <i>et al.</i> , 1984; Hen <i>et al.</i> , 1986; Satake <i>et al.</i> , 1988; Campbell and/or Villarreal, 1988
Retroviruses	Kriegler <i>et al.</i> , 1982, 1983; Levinson <i>et al.</i> , 1982; Kriegler <i>et al.</i> , 1983, 1984a, b, 1988; Bosze <i>et al.</i> , 1986; Miksicek <i>et al.</i> , 1986; Celander <i>et al.</i> , 1987; Thiesen <i>et al.</i> , 1988; Celander <i>et al.</i> , 1988; Choi <i>et al.</i> , 1988; Reisman <i>et al.</i> , 1989
Papilloma Virus	Campo <i>et al.</i> , 1983; Lusky <i>et al.</i> , 1983; Spandidos and/or Wilkie, 1983; Spalholz <i>et al.</i> , 1985; Lusky <i>et al.</i> , 1986; Cripe <i>et al.</i> , 1987; Gloss <i>et al.</i> , 1987; Hirochika <i>et al.</i> , 1987; Stephens <i>et al.</i> , 1987
Hepatitis B Virus	Bulla <i>et al.</i> , 1986; Jameel <i>et al.</i> , 1986; Shaul <i>et al.</i> , 1987; Spandau <i>et al.</i> , 1988; Vannice <i>et al.</i> , 1988
Human Immunodeficiency Virus	Muesing <i>et al.</i> , 1987; Hauber <i>et al.</i> , 1988; Jakobovits <i>et al.</i> , 1988; Feng <i>et al.</i> , 1988; Takebe <i>et al.</i> , 1988; Rosen <i>et al.</i> , 1988; Berkhout <i>et al.</i> , 1989; Laspia <i>et al.</i> , 1989; Sharp <i>et al.</i> , 1989; Braddock <i>et al.</i> , 1989
Cytomegalovirus (CMV)	Weber <i>et al.</i> , 1984; Boshart <i>et al.</i> , 1985; Foecking <i>et al.</i> , 1986
Gibbon Ape Leukemia Virus	Holbrook <i>et al.</i> , 1987; Quinn <i>et al.</i> , 1989

TABLE 2		
Inducible Elements		
Element	Inducer	References
MT II	Phorbol Ester (TFA) Heavy metals	Palmiter <i>et al.</i> , 1982; Haslinger <i>et al.</i> , 1985; Searle <i>et al.</i> , 1985; Stuart <i>et al.</i> , 1985; Imagawa <i>et al.</i> , 1987, Karin <i>et al.</i> , 1987; Angel <i>et al.</i> , 1987b; McNeill <i>et al.</i> , 1989
MMTV (mouse mammary tumor virus)	Glucocorticoids	Huang <i>et al.</i> , 1981; Lee <i>et al.</i> , 1981; Majors <i>et al.</i> , 1983; Chandler <i>et al.</i> , 1983; Ponta <i>et al.</i> , 1985; Sakai <i>et al.</i> , 1988
β -Interferon	poly(rI)x poly(rc)	Tavernier <i>et al.</i> , 1983
Adenovirus 5 <u>E2</u>	EIA	Imperiale <i>et al.</i> , 1984
Collagenase	Phorbol Ester (TPA)	Angel <i>et al.</i> , 1987a
Stromelysin	Phorbol Ester (TPA)	Angel <i>et al.</i> , 1987b
SV40	Phorbol Ester (TPA)	Angel <i>et al.</i> , 1987b
Murine MX Gene	Interferon, Newcastle Disease Virus	Hug <i>et al.</i> , 1988
GRP78 Gene	A23187	Resendez <i>et al.</i> , 1988
α -2-Macroglobulin	IL-6	Kunz <i>et al.</i> , 1989
Vimentin	Serum	Rittling <i>et al.</i> , 1989
MHC Class I Gene H-2 κ b	Interferon	Blanar <i>et al.</i> , 1989
HSP70	EIA, SV40 Large T Antigen	Taylor <i>et al.</i> , 1989, 1990a, 1990b
Proliferin	Phorbol Ester-TPA	Mordacq <i>et al.</i> , 1989
Tumor Necrosis Factor	PMA	Hensel <i>et al.</i> , 1989
Thyroid Stimulating Hormone α Gene	Thyroid Hormone	Chatterjee <i>et al.</i> , 1989

[0081] Where any cDNA insert is employed, one will typically include a polyadenylation signal to effect proper polyadenylation of the gene transcript. The nature of the polyadenylation signal is not believed to be crucial to the successful practice of the invention, and any such sequence may be employed such as human growth hormone and SV40

polyadenylation signals. In some aspects, however, a polyadenylation signal sequence is not included in a vector of the embodiments. For example, incorporation of such a signal sequence in lentiviral vectors (before a 3' LTR) can reduce resulting lentiviral titers.

5 [0082] A spacer sequence may be included in the nucleic acid construct. The presence of a spacer appears to enhance knockdown efficiency of miRNA (Stegmeier *et al.*, 2005). Spacers may be any nucleotide sequence. In some aspects, the spacer is GFP.

[0083] Also contemplated as an element of the expression cassette is a terminator. These elements can serve to enhance message levels and to minimize read through from the cassette into other sequences.

10 B. Selectable Markers

[0084] In certain embodiments of the invention, the cells contain nucleic acid constructs of the present invention, a cell may be identified *in vitro*, *ex vivo* or *in vivo* by including a marker in the expression construct. Such markers would confer an identifiable change to the cell permitting easy identification of cells containing the expression construct. 15 Usually the inclusion of a drug selection marker aids in cloning and in the selection of transformants, for example, genes that confer resistance to neomycin, puromycin, hygromycin, DHFR, GPT, zeocin and histidinol are useful selectable markers. Alternatively, enzymes such as herpes simplex virus thymidine kinase (*tk*) or chloramphenicol acetyltransferase (CAT) may be employed. Immunologic markers also can be employed. The selectable marker employed 20 is not believed to be important, so long as it is capable of being expressed simultaneously with the nucleic acid encoding a gene product. Further examples of selectable markers are well known to one of skill in the art.

III. Delivery of nucleic acid molecules and expression vectors

[0085] In certain aspects, vectors for delivery of nucleic acids of the 25 embodiments could be constructed to express these factors in cells. In a particular aspect, the following systems and methods may be used in delivery of nucleic acids to desired cell types.

A. Homologous recombination

[0086] In certain aspects of the embodiments, the vectors encoding nucleic acid molecules of the embodiments may be introduced into cells in a specific manner, for example, 30 via homologous recombination. Current approaches to express genes in stem cells have

involved the use of viral vectors (*e.g.*, lentiviral vectors) or transgenes that integrate randomly in the genome. These approaches have not been successful due in part because the randomly integrated vectors can activate or suppress endogenous gene expression, and/or the silencing of transgene expression. The problems associated with random integration could be partially
5 overcome by homologous recombination to a specific locus in the target genome.

[0087] Homologous recombination (HR), also known as general recombination, is a type of genetic recombination used in all forms of life in which nucleotide sequences are exchanged between two similar or identical strands of DNA. The technique has been the standard method for genome engineering in mammalian cells since the mid 1980s. The process
10 involves several steps of physical breaking and the eventual rejoining of DNA. This process is most widely used in nature to repair potentially lethal double-strand breaks in DNA. In addition, homologous recombination produces new combinations of DNA sequences during meiosis, the process by which eukaryotes make germ cells like sperm and ova. These new combinations of DNA represent genetic variation in offspring which allow populations to
15 evolutionarily adapt to changing environmental conditions over time. Homologous recombination is also used in horizontal gene transfer to exchange genetic material between different strains and species of bacteria and viruses. Homologous recombination is also used as a technique in molecular biology for introducing genetic changes into target organisms.

[0088] Homologous recombination can be used as targeted genome
20 modification. The efficiency of standard HR in mammalian cells is only 10^{-6} to 10^{-9} of cells treated (Capecchi, 1990). The use of meganucleases, or homing endonucleases, such as I-SceI have been used to increase the efficiency of HR. Both natural meganucleases as well as engineered meganucleases with modified targeting specificities have been utilized to increase HR efficiency (Pingoud and Silva, 2007; Chevalier *et al.*, 2002). Another path toward
25 increasing the efficiency of HR has been to engineer chimeric endonucleases with programmable DNA specificity domains (Silva *et al.*, 2011). Zinc-finger nucleases (ZFN) are one example of such a chimeric molecule in which Zinc-finger DNA binding domains are fused with the catalytic domain of a Type IIS restriction endonuclease such as FokI (as reviewed in Durai *et al.*, 2005; PCT/US2004/030606). Another class of such specificity molecules includes
30 Transcription Activator Like Effector (TALE) DNA binding domains fused to the catalytic domain of a Type IIS restriction endonuclease such as FokI (Miller *et al.*, 2011; PCT/IB2010/000154).

B. Nucleic acid delivery systems

[0089] One of skill in the art would be well equipped to construct a vector through standard recombinant techniques (see, for example, Sambrook *et al.*, 2001 and Ausubel *et al.*, 1996, both incorporated herein by reference). Vectors include but are not limited to, plasmids, cosmids, viruses (bacteriophage, animal viruses, and plant viruses), and artificial chromosomes (*e.g.*, YACs), such as retroviral vectors (*e.g.*, derived from Moloney murine leukemia virus vectors (MoMLV), MSCV, SFFV, MPSV, SNV *etc.*), lentiviral vectors (*e.g.*, derived from HIV-1, HIV-2, SIV, BIV, FIV *etc.*), adenoviral (Ad) vectors including replication competent, replication deficient and gutless forms thereof, adeno-associated viral (AAV) vectors, simian virus 40 (SV-40) vectors, bovine papilloma virus vectors, Epstein-Barr virus, herpes virus vectors, vaccinia virus vectors, Harvey murine sarcoma virus vectors, murine mammary tumor virus vectors, Rous sarcoma virus vectors.

1. Episomal Vectors

[0090] The use of plasmid- or liposome-based extra-chromosomal (*i.e.*, episomal) vectors may be also provided in certain aspects of the invention, for example, for reprogramming of somatic cells. Such episomal vectors may include, *e.g.*, oriP-based vectors, and/or vectors encoding a derivative of EBV-protein EBNA-1. These vectors may permit large fragments of DNA to be introduced to a cell and maintained extra-chromosomally, replicated once per cell cycle, partitioned to daughter cells efficiently, and elicit substantially no immune response.

[0091] In particular, EBNA-1, the only viral protein required for the replication of the oriP-based expression vector, does not elicit a cellular immune response because it has developed an efficient mechanism to bypass the processing required for presentation of its antigens on MHC class I molecules (Levitskaya *et al.*, 1997). Further, EBNA-1 can act *in trans* to enhance expression of the cloned gene, inducing expression of a cloned gene up to 100-fold in some cell lines (Langle-Rouault *et al.*, 1998; Evans *et al.*, 1997). Finally, the manufacture of such oriP-based expression vectors is inexpensive.

[0092] Other extra-chromosomal vectors include other lymphotropic herpes virus-based vectors. Lymphotropic herpes virus is a herpes virus that replicates in a lymphoblast (*e.g.*, a human B lymphoblast) and becomes a plasmid for a part of its natural life-cycle. Herpes simplex virus (HSV) is not a "lymphotropic" herpes virus. Exemplary

lymphotrophic herpes viruses include, but are not limited to EBV, Kaposi's sarcoma herpes virus (KSHV); Herpes virus saimiri (HS) and Marek's disease virus (MDV). Also other sources of episome-based vectors are contemplated, such as yeast ARS, adenovirus, SV40, or BPV.

5 **[0093]** One of skill in the art would be well equipped to construct a vector through standard recombinant techniques (see, for example, Maniatis *et al.*, 1988 and Ausubel *et al.*, 1994, both incorporated herein by reference).

10 **[0094]** Vectors can also comprise other components or functionalities that further modulate gene delivery and/or gene expression, or that otherwise provide beneficial properties to the targeted cells. Such other components include, for example, components that influence binding or targeting to cells (including components that mediate cell-type or tissue-specific binding); components that influence uptake of the vector nucleic acid by the cell; components that influence localization of the polynucleotide within the cell after uptake (such as agents mediating nuclear localization); and components that influence expression of the polynucleotide.

15 **[0095]** Such components also might include markers, such as detectable and/or selection markers that can be used to detect or select for cells that have taken up and are expressing the nucleic acid delivered by the vector. Such components can be provided as a natural feature of the vector (such as the use of certain viral vectors which have components or functionalities mediating binding and uptake), or vectors can be modified to provide such
20 functionalities. A large variety of such vectors are known in the art and are generally available. When a vector is maintained in a host cell, the vector can either be stably replicated by the cells during mitosis as an autonomous structure, incorporated within the genome of the host cell, or maintained in the host cell's nucleus or cytoplasm.

2. **Transposon-based system**

25 **[0096]** According to a particular embodiment the introduction of nucleic acids may use a transposon - transposase system. The used transposon - transposase system could be the well known Sleeping Beauty, the Frog Prince transposon - transposase system (for the description of the latter see *e.g.*, EP1507865), or the TTAA-specific transposon piggyback system.

[0097] Transposons are sequences of DNA that can move around to different positions within the genome of a single cell, a process called transposition. In the process, they can cause mutations and change the amount of DNA in the genome. Transposons were also once called jumping genes, and are examples of mobile genetic elements.

5 [0098] There are a variety of mobile genetic elements, and they can be grouped based on their mechanism of transposition. Class I mobile genetic elements, or retrotransposons, copy themselves by first being transcribed to RNA, then reverse transcribed back to DNA by reverse transcriptase, and then being inserted at another position in the genome. Class II mobile genetic elements move directly from one position to another using a
10 transposase to "cut and paste" them within the genome.

3. Viral Vectors

[0099] In generating recombinant viral vectors, non-essential genes are typically replaced with a gene or coding sequence for a heterologous (or non-native) protein or nucleic acid. Viral vectors are a kind of expression construct that utilizes viral sequences to introduce
15 nucleic acid and possibly proteins into a cell. The ability of certain viruses to infect cells or enter cells *via* pH-dependent or pH-independent mechanisms, to integrate their genetic cargo into a host cell genome and to express viral genes stably and efficiently have made them attractive candidates for the transfer of foreign nucleic acids into cells (*e.g.*, mammalian cells). Non-limiting examples of virus vectors that may be used to deliver a nucleic acid of certain
20 aspects of the present invention are described below.

[00100] Retroviruses have promise as gene delivery vectors due to their ability to integrate their genes into the host genome, transferring a large amount of foreign genetic material, infecting a broad spectrum of species and cell types and of being packaged in special cell-lines (Miller, 1992).

25 [00101] In order to construct a retroviral vector, a nucleic acid is inserted into the viral genome in the place of certain viral sequences to produce a virus that is replication-defective. In order to produce virions, a packaging cell line containing the gag, pol, and env genes but without the LTR and packaging components is constructed (Mann *et al.*, 1983). When a recombinant plasmid containing a cDNA, together with the retroviral LTR
30 and packaging sequences is introduced into a special cell line (*e.g.*, by calcium phosphate precipitation for example), the packaging sequence allows the RNA transcript of the

recombinant plasmid (*i.e.*, the vector genome) to be packaged into viral particles, which are then secreted into the culture media (Nicolas and Rubenstein, 1988; Temin, 1986; Mann *et al.*, 1983). The media containing the recombinant retroviruses is then collected, optionally concentrated, and used for gene transfer. Depending on the tropism of the envelope protein
5 used to cover the vector particles surface, retroviral vectors are able to infect a broad variety of cell types. However, integration and stable expression require the division of host cells (Paskind *et al.*, 1975).

[00102] Lentiviruses are complex retroviruses, which, in addition to the common retroviral genes *gag*, *pol*, and *env*, contain other genes with regulatory or structural function.
10 Lentiviral vectors are well known in the art (see, for example, Naldini *et al.*, 1996; Zufferey *et al.*, 1997; Blomer *et al.*, 1997; Giry-Laterriere *et al.*, 2011; U.S. Patents 6,013,516 and 5,994,136).

[00103] Recombinant lentiviral vectors are capable of infecting non-dividing cells and can be used for both *in vivo* and *ex vivo* gene transfer and expression of nucleic acid
15 sequences. For example, recombinant lentivirus capable of infecting a non-dividing cell wherein a suitable host cell is transfected with two or more vectors carrying the packaging functions, namely *gag*, *pol* and *env*, as well as *rev* and *tat* is described in U.S. Patent 5,994,136, incorporated herein by reference.

C. Nucleic acid Delivery

[00104] Introduction of a nucleic acid, such as DNA or RNA, into cells to be
20 programmed with the current invention may use any suitable methods for nucleic acid delivery for transformation of a cell, as described herein or as would be known to one of ordinary skill in the art. Such methods include, but are not limited to, direct delivery of DNA such as by *ex vivo* transfection (Wilson *et al.*, 1989, Nabel *et al.*, 1989), by injection (U.S. Patent Nos.
25 5,994,624, 5,981,274, 5,945,100, 5,780,448, 5,736,524, 5,702,932, 5,656,610, 5,589,466 and 5,580,859, each incorporated herein by reference), including microinjection (Harland and Weintraub, 1985; U.S. Patent No. 5,789,215, incorporated herein by reference); by electroporation (U.S. Patent No. 5,384,253, incorporated herein by reference; Tur-Kaspa *et al.*,
1986; Potter *et al.*, 1984); by calcium phosphate precipitation (Graham and Van Der Eb, 1973;
30 Chen and Okayama, 1987; Rippe *et al.*, 1990); by using DEAE-dextran followed by polyethylene glycol (Gopal, 1985); by direct sonic loading (Fechheimer *et al.*, 1987); by liposome mediated transfection (Nicolau and Sene, 1982; Fraley *et al.*, 1979;

Nicolau *et al.*, 1987; Wong *et al.*, 1980; Kaneda *et al.*, 1989; Kato *et al.*, 1991) and receptor-mediated transfection (Wu and Wu, 1987; Wu and Wu, 1988); by microprojectile bombardment (PCT Application Nos. WO 94/09699 and 95/06128; U.S. Patent Nos. 5,610,042; 5,322,783 5,563,055, 5,550,318, 5,538,877 and 5,538,880, and each incorporated
5 herein by reference); by agitation with silicon carbide fibers (Kaeppeler *et al.*, 1990; U.S. Patent Nos. 5,302,523 and 5,464,765, each incorporated herein by reference); by *Agrobacterium*-mediated transformation (U.S. Patent Nos. 5,591,616 and 5,563,055, each incorporated herein by reference); by desiccation/inhibition-mediated DNA uptake (Potrykus *et al.*, 1985), and any combination of such methods. Through the application of
10 techniques such as these, organelle(s), cell(s), tissue(s) or organism(s) may be stably or transiently transformed.

1. Liposome-Mediated Transfection

[00105] In a certain embodiment of the invention, a nucleic acid may be entrapped in a lipid complex such as, for example, a liposome. Liposomes are vesicular structures
15 characterized by a phospholipid bilayer membrane and an inner aqueous medium. Multilamellar liposomes have multiple lipid layers separated by aqueous medium. They form spontaneously when phospholipids are suspended in an excess of aqueous solution. The lipid components undergo self-rearrangement before the formation of closed structures and entrap water and dissolved solutes between the lipid bilayers (Ghosh and Bachhawat, 1991). Also
20 contemplated is an nucleic acid complexed with Lipofectamine (Gibco BRL) or Superfect (Qiagen). The amount of liposomes used may vary upon the nature of the liposome as well as the cell used, for example, about 5 to about 20 μ g vector DNA per 1 to 10 million of cells may be contemplated.

[00106] Liposome-mediated nucleic acid delivery and expression of foreign DNA
25 *in vitro* has been very successful (Nicolau and Sene, 1982; Fraley *et al.*, 1979; Nicolau *et al.*, 1987). The feasibility of liposome-mediated delivery and expression of foreign DNA in cultured chick embryo, HeLa and hepatoma cells has also been demonstrated (Wong *et al.*, 1980).

[00107] In certain embodiments of the invention, a liposome may be complexed
30 with a hemagglutinating virus (HVJ). This has been shown to facilitate fusion with the cell membrane and promote cell entry of liposome-encapsulated DNA (Kaneda *et al.*, 1989). In other embodiments, a liposome may be complexed or employed in conjunction with nuclear

non-histone chromosomal proteins (HMG-1) (Kato *et al.*, 1991). In yet further embodiments, a liposome may be complexed or employed in conjunction with both HVJ and HMG-1. In other embodiments, a delivery vehicle may comprise a ligand and a liposome.

2. Electroporation

5 **[00108]** In certain embodiments of the present invention, a nucleic acid is introduced into an organelle, a cell, a tissue or an organism *via* electroporation. Electroporation involves the exposure of a suspension of cells and DNA to a high-voltage electric discharge. Recipient cells can be made more susceptible to transformation by mechanical wounding. Also the amount of vectors used may vary upon the nature of the cells used, for example, about 5 to
10 about 20 µg vector DNA per 1 to 10 million of cells may be contemplated.

[00109] Transfection of eukaryotic cells using electroporation has been quite successful. Mouse pre-B lymphocytes have been transfected with human kappa-immunoglobulin genes (Potter *et al.*, 1984), and rat hepatocytes have been transfected with the chloramphenicol acetyltransferase gene (Tur-Kaspa *et al.*, 1986) in this manner.

15 3. Calcium Phosphate

[00110] In other embodiments of the present invention, a nucleic acid is introduced to the cells using calcium phosphate precipitation. Human KB cells have been transfected with adenovirus 5 DNA (Graham and Van Der Eb, 1973) using this technique. Also in this manner, mouse L(A9), mouse C127, CHO, CV-1, BHK, NIH3T3 and HeLa cells were
20 transfected with a neomycin marker gene (Chen and Okayama, 1987), and rat hepatocytes were transfected with a variety of marker genes (Rippe *et al.*, 1990).

4. DEAE-Dextran

[00111] In another embodiment, a nucleic acid is delivered into a cell using DEAE-dextran followed by polyethylene glycol. In this manner, reporter plasmids were
25 introduced into mouse myeloma and erythroleukemia cells (Gopal, 1985).

D. Cell culturing

[00112] Generally, cells of the present invention are cultured in a culture medium, which is a nutrient-rich buffered solution capable of sustaining cell growth.

[00113] Culture media suitable for isolating, expanding and differentiating stem cells according to the method described herein include but not limited to high glucose Dulbecco's Modified Eagle's Medium (DMEM), DMEM/F-12, Liebovitz L-15, RPMI 1640, Iscove's modified Dulbecco's media (IMDM), and Opti-MEM SFM (Invitrogen Inc.).

5 Chemically Defined Medium comprises a minimum essential medium such as Iscove's Modified Dulbecco's Medium (IMDM) (Gibco), supplemented with human serum albumin, human Ex Cyte lipoprotein, transferrin, insulin, vitamins, essential and non essential amino acids, sodium pyruvate, glutamine and a mitogen is also suitable. As used herein, a mitogen refers to an agent that stimulates cell division of a cell. An agent can be a chemical, usually

10 some form of a protein that encourages a cell to commence cell division, triggering mitosis. In one embodiment, serum free media such as those described in U.S. Ser. No. 08/464,599 and WO96/39487, and the "complete media" as described in U.S. Pat. No. 5,486,359 are contemplated for use with the method described herein. In some embodiments, the culture medium is supplemented with 10% Fetal Bovine Serum (FBS), human autologous serum,

15 human AB serum or platelet rich plasma supplemented with heparin (2U/ml). Cell cultures may be maintained in a CO₂ atmosphere, *e.g.*, 5% to 12%, to maintain pH of the culture fluid, incubated at 37°C in a humid atmosphere and passaged to maintain a confluence below 85%.

IV. Examples

[00114] The following examples are included to demonstrate preferred embodiments

20 of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed

25 and still obtain a like or similar result without departing from the spirit and scope of the invention.

EXAMPLE 1 – MATERIALS AND METHODS

[00115] **Construction of miRNA-containing plasmids and lentiviral vectors.** The plasmids were constructed using the gateway system as described previously (Myburgh *et al.*,

30 2014). With the exception of MGST2, spacer sequences were amplified by PCR using Herculase II polymerase (Agilent, Santa Clara, CA) with forward and reverse primers carrying respectively EcoRI and XhoI restriction sites and cloned into a pENTR vector (Invitrogen) by

digestion / ligation steps (Table 3). Most of the primers used for the cloning of spacers were designed with AttB1 (forward primer) and AttB2 (reverse primer) recombination sites at the 5' extremity (Table 4).

5 [00116] The MGST2 spacer was obtained from pOTB7-MGST2 plasmid (transomic) by EcoRI / XhoI restriction digestion and subsequent ligation into the pENTR vector. mirGE hairpins were amplified using the same strategy and forward and reverse primers carrying respectively SpeI and BamHI restriction sites. Elements of the miRGE hairpins can be seen in Table 5. miRGE hairpin concatenates were made using different couples of restriction enzymes on the miRGE primers or by blunt ligation as in Sun et al, 2006. Each new
10 miRGE addition was verified by sequencing the pENTR vector. The amplicon parts of each clone, including spacer and miRGE hairpins were systematically verified by sequencing. The oligos for the miRGE PCR template and primers were obtained from Microsynth (Balgach, Switzerland). miRGE hairpin template sequences targeting CCR5, GFP and p22^{phox} are available in Table 6.

15 [00117] The final lentivector plasmid was generated by an LR Clonase II (Invitrogen, Carlsbad, CA)-mediated recombination of a pENTR plasmid containing the human UBI promoter (pENTR-L4-UBI-L1R) or the Elongation Factor 1 short promoter (pENTR-L4-EFs-L1R) and a lentivector destination cassette (pCWX-R4dEST-R2-PC) containing an additional transcription unit encoding for mCherry marker gene upon human
20 phosphoglycerate kinase 1 (PGK) promoter. The GFP target sequence—AAGAACGGCATCAAGGTGAACT (SEQ ID NO:57)—was taken from a previous publication (Mottet-Osman *et al.*, 2007). The human CCR5 (Genbank NM_000579.3) target sequences (T7) 5'aAGTGTC AAGTCCAATCTATGA (SEQ ID NO:58) was previously used (Myburgh *et al.*, 2014).

25

Table 3: Lentivectors and titers.

Lentivector	Titer (TU/mL)
pCWX-UBI-mcherry (control vector)	3.55E+06
pCWX-UBI-No spacer-mirGE CCR5-7-PGK-mCherry	1.02E+07
pCWX-UBI-GFP-mirGE CCR5-7-PGK-mCherry	4.66E+06
pCWX-UBI-mirGE CCR5-7-GFP-PGK-mCherry	1.17E+07
pCWX-UBI-MGST2-mirGE CCR5-7-PGK-mCherry	7.80E+05
pCWX-UBI-NGFR-mirGE CCR5-7-PGK-mCherry	1.94E+05
pCWX-UBI-CD4 R1-mirGE CCR5-7-PGK-mCherry	1.80E+06
pCWX-UBI-CD4 R2-mirGE CCR5-7-PGK-mCherry	2.76E+06
pCWX-UBI-CD4 R3-mirGE CCR5-7-PGK-mCherry	2.52E+06
pCWX-UBI-HO-1-mirGE CCR5-7-PGK-mCherry	1.60E+06
pCWX-UBI-H2B-mirGE CCR5-7-PGK-mCherry	1.22E+07
pCWX-UBI-stopGFP-mirGE CCR5-7-PGK-mCherry	3.54E+06
pCWX-UBI-GFPpart1-mirGE CCR5-7-PGK-mCherry	1.56E+06
pCWX-UBI-GFPpart2-mirGE CCR5-7-PGK-mCherry	1.59E+06
pCWX-UBI-MGST2-mirGE CYBA 222-PGK-mCherry	1.57E+06
pCWX-UBI-stopGFP-mirGE CYBA 222-PGK-mCherry	2.31E+06
pCWX-UBI- MGST2-mirGE-CCR5-777-PGK-mCherry	1.34E+07
pCWX-UBI- MGST2-mirGE-CCR5-777GFP-PGK-mCherry	1.20E+07
pCWX-UBI- MGST2-mirGE-CCR5-7777-PGK-mCherry	1.10E+05
pCWX-UBI- MGST2-mirGE-CCR5-7777GFP-PGK-mCherry	1.28E+07
pCWX-UBI-No spacer-mirGE CCR5-777-PGK-mCherry	6.81E+06
pCWX-UBI-mirGE CCR5-777-GFP-PGK-mCherry	1.10E+07
pCWX-UBI-H2B-mirGE CCR5-777-PGK-mCherry	5.06E+06
pCWX-UBI- stopGFP-mirGE-CCR5-777-PGK-mCherry	1.00E+06
pCWX-UBI- stopGFP-mirGE-CCR5-777GFP-PGK-mCherry	1.84E+05
pCWX-UBI- stopGFP-mirGE-CCR5-7777-PGK-mCherry	1.98E+06
pCWX-UBI- stopGFP-mirGE-CCR5-7777GFP-PGK-mCherry	1.12E+06
pCWX-UBI-stopGFP-mirGEGFP-PGK-mCherry	9.02E+05
pCWX-EFs-No spacer-mirGE CCR5-7-PGK-mCherry	9.25E+06
pCWX-EFs-GFP-mirGE CCR5-7-PGK-mCherry	1.21E+07
pCWX-EFs-GFP-mirGE CCR5-777-PGK-mCherry	1.27E+07
pCWX-EFs-mirGE CCR5-7-GFP-PGK-mCherry	6.82E+06
pCWX-EFs-mirGE CCR5-777-GFP-PGK-mCherry	4.75E+06
pCWX-EFs-No spacer-mirGE CCR5-777-PGK-mCherry	6.02E+06

Table 4: Cloning primers

Amplicon	Primer forward 5'-3' (AttB1-EcoRI)	Primer reverse 5'-3' (AttB2-XhoI)
GFP	GGGGACAAGTTTGTACAAAAAAGC AGGCTGAATTCTGAGCAAGGGCGA GGAGCTGT (SEQ ID NO:1)	GGGGACCACTTTGTACAAGA AAGCTGGGTCTCGAGCTTGT ACAGCTCGTCCATGCCG (SEQ ID NO:2)
stopGFP	GGGGACAAGTTTGTACAAAAAAGC AGGCTTCTAGAATGGATGTAAGTA GGTGAGTGAGCA (SEQ ID NO:3)	GGGGACCACTTTGTACAAGA AAGCTGGGTCTCGAGCTTGT ACAGCTCGTCCATGCCGAGA (SEQ ID NO:4)
GFPpart1	GGGGACAAGTTTGTACAAAAAAGC AGGCTGAATTCTGAGCAAGGGCGA GGAGCTGT (SEQ ID NO:5)	GGGGGCTCGAGTCGCCCTCG AACTTCACCTCG (SEQ ID NO:6)
GFPpart2	GGGGGAATTCCACCCTGGTGAAC CGCATCGA (SEQ ID NO:7)	GGGGACCACTTTGTACAAGA AAGCTGGGTCTCGAGCTTGT ACAGCTCGTCCATGCCG (SEQ ID NO:8)
INGFR	GGGGACCACTTTGTACAAGAAAGC TGGGTCTCGAGCTAGAGGATCCCC CTGTTCCACCT (SEQ ID NO:9)	GGGGACAAGTTTGTACAAAA AAGCAGGCTGAATTCTCACC ATGGGGCAGGTGCCACCGG (SEQ ID NO: 10)
HO-1	GGGGACAAGTTTGTACAAAAAAGC AGGCTGAATTCTCACCATGGAGCG TCCGCAACCCGA (SEQ ID NO: 11)	GGGGACCACTTTGTACAAGA AAGCTGGGTCTACAGCAACT GTCGCCACC (SEQ ID NO: 12)
CD4R1	GGGGACAAGTTTGTACAAAAAAGC AGGCTGAATTCTAATAGTGACCAC TCCTGGCTAATTTTGTATTTTCA GTAGAGATAGGG (SEQ ID NO: 13)	GGGGACCACTTTGTACAAGA AAGCTGGGTCTCGAGGGTGA AACCCTTCTCTACTAAAAAT ACAAAATTAGCCGGGCACA (SEQ ID NO: 14)
CD4R2	–	GGGGACCACTTTGTACAAGA AAGCTGGGTCTCGAGCCGCA CTCCAGCCTCGGCGACAGAG CAAGACTCTATCTCA (SEQ ID NO: 15)
CD4R3	–	GGGGACCACTTTGTACAAGA AAGCTGGGTCTCGAGTCGGG AGTACGAGACCAGCCTGGCC AACATAGTCAAATCC (SEQ ID NO: 16)

H2B	GGGGACAAGTTTGTACAAAAAAGC AGGCTGAATTCATGCCAGAGCCAG CGAAGTC (SEQ ID NO: 17)	GGGGACCACTTTGTACAAGA AAGCTGGGTCTCGAGGTGTA CTTGGTGACGGCCTTA (SEQ ID NO: 18)
miRGE 1st hairpin	CAGAAGGGGATCCATCGATACTAG TGGTGATAGCAATGTCAGCAGTGC CT (SEQ ID NO: 19)	AGTAGCTTCTAGAGTAGAGT ATGGTCAACCTTACTT (SEQ ID NO: 20)
miRGE 2nd hairpin	CAGAAGGGGATCCGGTGATAGCAA TGTCAGCAGTGCCT (SEQ ID NO: 21)	AGTAGCTACTAGTGTAGAGT ATGGTCAACCTTACTT (SEQ ID NO: 22)
miRGE 3rd hairpin	CAGAAGGCTCGAGGGTGATAGCAA TGTCAGCAGTGCCT (SEQ ID NO: 23)	AGTAGCTGGATCCGTAGAGT ATGGTCAACCTTACTT (SEQ ID NO: 24)

Table 5: miRGE hairpin components

mir-16 flanking sequence	GGTGATAGCAAT	SEQ ID NO: 25
Lower stem sequence	CAGCAGTGCCT	SEQ ID NO: 26
Lower stem sequence	TCAGCAGTGCCT	SEQ ID NO: 27
Lower stem sequence	GTCAGCAGTGCCT	SEQ ID NO: 28
Lower stem sequence	CGTCAGCAGTGCCT	SEQ ID NO: 29
Lower stem sequence	ACGTCAGCAGTGCCT	SEQ ID NO: 30
mir-30 loop sequence	GTGAAGCCACAGATG	SEQ ID NO: 31

5 **Table 6: miRGE backbone sequences**

Template 5'-3'	
miRGE CCR5-7	GGT GAT AGC AAT GTC AGC AGT GCC TTC ATA GAT TGG ACT TGA CAC TTG TGA AGC CAC AGA TGA AGT GTC AAG CCC AAT CTA TGC AAG TAA GGT TGA CCA TAC TCT AC (SEQ ID NO: 32)
miRGE GFP	GGT GAT AGC AAT GTC AGC AGT GCC TAG TTC ACC TTG ATG CCG TTC TTG TGA AGC CAC AGA TGA AGA ACG GCA CCA AGG TGA ACC

	AAG TAA GGT TGA CCA TAC TCT AC (SEQ ID NO: 33)
miRGE p22phox	GGT GAT AGC AAT GTC AGC AGT GCC TAC ATG GCC CAC TCG ATC TGC CCG TGA AGC CAC AGA TGG GGC AGA TCG CGT GGG CCA TGC AAG TAA GGT TGA CCA TAC TCT AC (SEQ ID NO: 34)

[00118] Lentiviral vector production and titration. Lentiviral vector stocks were generated using transient transfection of HEK 293T cells with the specific lentivector transfer plasmid, the psPAX2 plasmid encoding gag/pol and the pCAG-VSVG envelope plasmid, as previously described (Giry-Laterriere *et al.*, 2011a, Giry-Laterriere *et al.*, 2011a). Lentivector titration was performed using transduction of HT-1080 cells followed by flow cytometry quantification of mcherry-positive cells five days after transduction, as previously described (Giry-Laterriere *et al.*, 2011a, Giry-Laterriere *et al.*, 2011a).

[00119] Cell culture and knockdown analysis. All cell lines were cultured in high glucose Dulbecco's modified eagle medium (Sigma) supplemented with 10% fetal calf serum, 1% Penicillin, 1% Streptomycin, and 1% L-glutamine. For each knockdown assay, cells were analyzed at least 5 days after transduction. For CCR5 knockdown studies, a subclone of HeLa-derived TZMbl cells (AIDS Repository, Germantown, MD), expressing high levels of human CCR5, named here HeLa R5, was used. For GFP knockdown, the same cells were used after GFP transduction at 1 copy of the vector and sorting of the GFP positive cells. CCR5 expression was detected using an anti-human CCR5-APC-antibody, (BD Pharmingen Cat. 550856) and flow cytometry analysis using FACS Cyan (Beckman Coulter). GFP expression was assessed on the same flow cytometer using GFP fluorescence median. Briefly, HeLa cells were transduced at 0.2 MOI with the miRGE-based knockdown vector to avoid the presence of a high copy number of the vector per cell and obtain comparable conditions. GFP or CCR5 expression was compared between the transduced and the remaining untransduced population of cells and expressed as a percentage of CCR5 expression relatively to the untransduced population.

[00120] Real-time Quantitative Reverse Transcriptase Polymerase Chain Reaction. Cells or organotypic explant of organ of Corti were harvested and mRNA was extracted using Qiagen RNeasy mini kit following the manufacturer's instructions. RNA concentration was determined using a Nanodrop. 500 ng was used for cDNA synthesis using Takara PrimeScript RT reagent Kit following manufacturer's instruction. Real-time PCR was performed using SYBR green assay on a 7900HT SDS system from ABI. The efficiency of each primer was verified with serial dilutions of cDNA. Relative expression levels were calculated by normalization to the geometric mean of the two house-keeping genes GAPDH and EF1a and the GAG lentivector gene. The highest normalized relative quantity was arbitrarily designated as a value of 1.0. Fold changes were calculated from the quotient of means of these normalized quantities and reported as \pm SEM. Sequences of the qPCR primers used are provided in Table 7.

Table 7. qPCR primers

Amplicon	Primer forward 5'-3'	Primer reverse 5'-3'
Cyba (p22phox)	TGGACGTTTCACACAGTGGT (SEQ ID NO: 35)	TGGACCCCTTTTTCTCTTT (SEQ ID NO: 36)
miRGE pri-miRNA	GGTGATAGCAATGTCAGCAGTGCCT (SEQ ID NO: 37)	GTAGAGTATGGTCAACCTTACTT (SEQ ID NO: 38)
mature miRGE	LNA modified proprietary sequence (exiqon)	
GAG	GGAGCTAGAACGATTTCGCAGTTA (SEQ ID NO: 39)	GGTTGTAGCTGTCCAGTATTTGTC (SEQ ID NO: 40)
EEF1a	TCCACTTGGTCGCTTTTGTCT (SEQ ID NO: 41)	CTTCTTGTCCACAGCTTTGATGA (SEQ ID NO: 42)
GAPDH	TCCATGACAACCTTTGGCATTG (SEQ ID NO: 43)	CAGTCTTCTGGGTGGCAGTGA (SEQ ID NO: 44)

[00121] Quantitative Reverse Transcriptase Polymerase Chain Reaction for mature miRNA detection. HeLa R5 cells were transduced at 0.2 MOI with lentivectors carrying the different SMIG. Transduced population (expressing mCherry) was sorted by FACS resulting in a homogeneous cell population carrying a single copy of the vector / cell. Total RNA was extracted using Trizol Reagent (Ambion) according to manufacturer instructions. RNA concentration was determined using a Nanodrop. 100 ng of RNA was used for the reverse transcription (miRCURY LNATM miRNA PCR, Polyadenylation and cDNA synthesis kit (exiqon)). Reverse transcription was followed by real-time PCR amplification

(ExiLENT SYBR® Green master mix kit (exiqon)) with LNA™ enhanced primers. Relative expression levels of the mature miRGE were calculated by normalization to the geometric mean of the two house-keeping miRNA (U6 and RNU5G). Fold changes were calculated from the quotient of means of these normalized quantities and reported as ±SEM. Sequences of the
5 LNA™ enhanced primers were not provided by the manufacturer.

[00122] Reactive Oxygen Species measurement by Amplex Red assay. PLB-985 cells were cultured in RPMI medium (Gibco), transduced as described above and differentiated into neutrophil-like cells during 5 days in presence of 1.25% DMSO. Levels of H₂O₂ produced by intact PLB-985 cells after stimulation of NOX2 with 100nM phorbol myristate acetate (PMA) were then measured using Amplex Red fluorescence as previously
10 described (Jaquet *et al.*, 2011). Fluorescence was measured with a FluoSTAR OPTIMA, BMG labtech instrument at 37 °C.

[00123] Organotypic culture and transduction of rat organ of Corti. Three days old Wistar Rats were decapitated and the heads were cut sagittally to remove the brain.
15 The two otic capsules were isolated and transferred into ice-cold Hank's balanced salt solution (HBSS) (Invitrogen, USA) for sterile dissection under a binocular microscope (Nikon SMZ800, Japan) with forceps (World Precision Instruments, USA). After bone removal, the cochlea was transferred to a Transwell-Clear insert (6-well format, Corning, USA) with a permeable polyester membrane (0.4 µm pore size). The membranes were pre-coated with
20 Celltak (Corning, USA) according to manufacturer's protocol. The organ of Corti (OC) was then separated from stria vascularis and the modiulus and plated on the insert, with the hair cells facing up. Dissection medium was carefully removed and 1.5 ml otic culture medium: (DMEM/F12 (Invitrogen, USA), 0.01% Ampicillin (Sigma, USA) and 10% fetal bovine serum (Invitrogen, USA) was added to the lower compartment under the insert membrane. On the
25 following day, the medium on the insert was removed and they were transferred into an empty well. For the transduction, 200 µl otic culture medium was added on the explant together with 70 µl DMEM/F12 (Invitrogen/USA) containing 10⁶, 5x10⁶ or 10⁷ particles of the stopGFP triple miRGE hairpin lentivector targeting p22phox. After 30 minutes of incubation at 37°C and 5% CO₂, 1.5 ml otic culture medium was added to the lower compartment. The medium
30 was replaced with fresh otic culture medium on the two following days. 5 days after the initial transduction, cochlear explants were either detached with trypsin for mRNA isolation or fixed for 10 minutes with 4% paraformaldehyde for immunostainings.

[00124] Immunostaining and confocal microscopy of rat organotypic culture of organ of Corti. Cochlear explants were fixed with 4% paraformaldehyde for 10 minutes at room temperature. Explants were transferred (by cutting the insert membrane) to a 24 well plate, washed three times with PBS and permeabilized with 3% Triton-X 100 for 30 minutes. Cochlear explants were immersed in a blocking buffer containing 2% bovine serum albumin (BSA) and 0.01% Triton-X 100 for 1 hour at room temperature. Explants were incubated with the anti-MyoVIIa (1:500, rabbit; Proteus, USA) antibody in blocking buffer overnight at 4°C. On the following day, tissues were rinsed three times with PBS and incubated with the secondary antibody anti-rabbit Alexa Fluor 488 (1:500; Invitrogen, USA) in blocking buffer for 2 hours at room temperature. Explants were again washed 3 times with PBS and mounted on a glass slide with Fluoroshield containing DAPI (Sigma Aldrich, USA). The labelled cells were visualized with a confocal laser-scanning microscope (Zeiss LSM710) equipped with a CCD camera (Leica Microsystems) with a Planapochromat 10x/0.3 NA objective.

[00125] Knockdown of CCR5 in humanized mice leukocytes. Human CD34 isolated from cord blood using magnetic beads (Miltenyi) were cultivated in activation medium (Cell Gro medium containing 20 ng/mL recombinant human [rh] stem cell factor (SCF), 20 ng/mL rh Flt3-L, 20 ng/mL rh interleukin-3 [IL-3], 20 ng/mL rh TPO1, 1% v/v penicillin-streptomycin [Penstrep]). The cells were seeded in a 24-well plate at 1.0×10^6 cells/mL for 24 h at 37°C in activation medium for pre-stimulation. On the next day for transduction, Lentiblast B was added to the medium in a dilution of 1:1,000. Used MOI for transduction was 50. One well with 0.1×10^6 cells was not transduced and served as negative control. CD34 cells were cultivated for 48 h and then harvested except the transduction controls. The cells designated for transplantation were frozen and stored until transplantation of newborn NGS mice in liquid N2. Newborn NGS mice were then irradiated with 1 Gy and then transplanted with 260,000 CD34+ cells. Week 23 after birth, engraftment check was done by analyzing peripheral blood from the mice. CCR5 expression was then investigated at 28 weeks old using the following antibodies: huCD45 FITC (304006), CD3 AF700 (300424), CD4 PE-CY7 (300512), CD8 BV421 (301036), and CCR5 APC (359122) (or isocontrol #400611) from BioLegend.

[00126] Prediction of the minimum free energy of spacer sequences. The minimum free energy (MFE) of spacers was calculated using RNA fold web server (Institute

for Theoretical Chemistry, University of Vienna, available on the world wide web at rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi). To allow comparison of MFE between spacers, obtained values were divided by the length of the spacer.

[00127] Calculation of the efficiency of concatenation of triple hairpin concatenates. The concatenation efficiency of triple hairpin constructs (E) was calculated according to the formula $E = \ln(CP) / \ln(KP)$ where KP and CP are respectively the knockdown of CCR5 obtained with single and triple hairpin constructs. If E=3, a fully additive effect of the hairpins is observed in the concatenate. If E=1 the triple hairpin construct is as efficient as the single hairpin construct and no additive effect of the hairpins concatenation is observed.

[00128] Statistical analysis. Statistical analyses were performed using GraphPad Prism 5.04 (GraphPad Software, La Jolla, CA). One-way analysis of variance followed by Bonferroni's multiple comparison tests, as well as t-tests (non-parametric, Mann-Whitney U-test).

15

EXAMPLE 2 – RESULTS

[00129] A spacer sequence is required for polymerase II promoter-driven miRNA mediated target gene knockdown. To optimize the miRGE-based knockdown and better understand the role of the spacer, the Green Fluorescent Protein (GFP) sequence was placed either on the 5' or on the 3'-end of the miRGE hairpin sequences in a lentiviral vector (Fig. 1a). HeLa cells expressing CCR5 (R5 cells) were transduced at an MOI of 0.2 to reduce statistical probabilities of having more than one copy of transgene/cell (Fig. 1b). Both single and a triple hairpins targeting CCR5 were used. Two different polII-dependent promoters were used: the ubiquitin promoter (UBI) and a spliced version of the elongation factor 1 promoter, EFs²⁵

20

25

(cgatggctccggtgcccgtagtgggcagagcgcacatgccacagtcgccgagaagtggggggaggggtcggcaattgaac cggtgcctagagaaggtggcgcggggtaaacgggaaagtgatgctgtgtactggctccgccttttcccgaggggtgggggagaacc gtatataagtgcagtagtcgccgtgaacgttcttttcgcaacggggttggcccgagaacacaggtgctgtgacgcg; SEQ ID NO: 45). When the UBI promoter was used, absence of the spacer entirely precluded CCR5 knockdown, even when three hairpins were used (Fig. 1c).

[00130] The efficacy of the spacer depends on its position. With the spacer between the promoter and the miRNA, an efficient CCR5 knockdown was observed with a single hairpin, which was markedly enhanced with a concatenated triple hairpin construct. When the spacer was put in the 3' position of the miRNA gene, the single hairpin showed a
5 decreased CCR5 knockdown efficiency, while the increased knockdown effect of the concatenate was entirely lost (Fig. 1c and 1e). The situation was slightly different for the EFs promoter (Fig. 1d). The efficacy of a single hairpin did not depend on the presence of a spacer, but no additive effect of the triple concatenate was observed in the absence of a spacer (Fig. 1e). In contrast, with the spacer between the promoter and the hairpins, a maximal effect of the
10 triple concatenate was achieved while less pronounced effect was observed with the spacer in 3'.

[00131] Together, the data demonstrate that a spacer sequence – preferentially located in 5' of the miRNA - is required to drive efficient knockdown via two types of polIII-dependent promoters. The spacer is also required for additive effects of the hairpin
15 concatenation (Fig. 1e).

[00132] Efficiency of miRNA-based knockdown depends on the spacer sequence. The potency of several coding and noncoding spacer sequences was assessed (Fig. 2a; Table 8). Five miRGE minigenes with coding sequences were generated as spacers: Green Fluorescent Protein (GFP), Microsomal Glutathione S-transferase-2 (MGST2), truncated
20 Nerve Growth Factor Receptor (dNGFR), Heme oxygenase-1 (HO-1), and Histone 2B (H2B) cDNAs (Table 9). The first intron of the CD4 gene, iCD4, was used as a noncoding spacer sequence. Lentivectors carrying the respective minigenes were used to transduce HeLa R5 cells. A significant knockdown of the CCR5 protein was observed in the transduced population of cells with all coding sequences (MGST, LNGFR, HO-1 and H2B spacers). The GFP
25 sequence spacer resulted in the highest knockdown of CCR5. The worst performing spacers were iCD4 and H2B (<10% knockdown), while the other coding sequences resulted in an intermediate efficiency (Fig. 2a).

Table 8. Spacer sequences and biophysical features

[00133] In an attempt to identify specific regions within spacer sequences which have an effect on the knockdown efficiency, truncated forms of GFP (GFP1, GFP2) and of the iCD4 (iCD42, iCD43) were designed (Fig. 2b and 2c). Remarkably, the activity of the truncated GFP1 and GFP2 was comparable to full length GFP (Fig. 2b). The situation was different for the CD4 intron, where the shorter amplicons (iCD42 and iCD43) resulted in a moderate but significant knockdown of CCR5 (Fig. 2c). However, these truncated CD4 first intron sequences were still inefficient spacers when compared to sequences of similar length (GFP1 or GFP2) (Fig. 2b and Fig. 2c). These results demonstrate that the spacer activity does not simply depend on the length, but that the nucleotide sequence also seems to determine its efficiency. There was no correlation observed between the predicted minimum free energy (MFE) of spacers and

Spacer	Length (bp)	Predicted MFE Kcal/mol	% GC	coding	Comments
Green Fluorescent protein (GFP)	717	-264.6	61.11	YES	Reference spacer
Truncated GFP1	369	-142.2	62.87		
GFP2	388	-116.4	59.53		
Stop codons in the 3 reading frame after the start codon of GFP (stopGFP)	732	-	-	NO	non coding form
Microsomal Glutathion Transferase-2 (MGST2)	726	-197.7	43.92	YES	Resistance to Busulfan
Truncated form of the Nerve Growth Factor Receptor (deltaNGFR)	843	-397.7	66.86	YES	Pre-implantation selection
Heme Oxygenase (HO-1)	863	-336.2	61.24	YES	Cytoprotection
Histone2B (H2B)	378	-123.7	58.99	YES	Neutral
Amplicons from the 1st intron of the CD4 gene iCD41	793	-235.9	46.71	NO	Neutral ?
iCD42	620	-189.2	45.48		
iCD43	380	-136	49.36		

the knockdown efficiency (Fig. 7a). GC content of the spacer sequences was assessed and found that spacers with higher GC content tended to correlate with the higher knockdown efficiency (Fig. 7b).

Table 9. Spacer sequences

Spacer	Sequence
GFP	ATGGATGTAAGTAGGTAGTGAGCAAGGGGAGGAGCTGTTACCGGGTGGTGCCCATCTTGGTGGAGCTGGACGGCGACGTAAACGGCCACAAGTTTCAG CGTGTCCGGGAGGGGAGGGCGATGCCACCTACGGCAAGCTGACCCCTGAAGTTTCATCTGCACCACCGGCAAGCTGCCCGTGCCTGGCCCAACCCCTCGTGA CCACCTTGACCTACGGGTGCAGTGTCTCAGCGCTACCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCGGAAGGCTACGTCCAGGAG CGCACCATCTTCAAGGACGACGGCACTACAAGACCCGCGGAGTGAAGTTCGAGGGGACACCCCTGGTGAACCGGATCGAGCTGAAGGGCATCG ACTTCAAGGAGGACGGCAACATCTTGGGGCAAGCTGGAGTACAATACAAGCCACAACGTTCTATATCATGGCCGACACGAGAAGAACGGCATCAAG GTGAACCTCAAGATCCGCCACAACATCGAGGACGGCAGCTGACCTCGCCGACCACTACCAGCAGAACACCCCATCGGGCAGGCCCTGCTGTCTGCC CGACAAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAACCCCAACGAGAACGCGATCACATGGTCTGTTGAGTTCGTACCCGCCCGGGGATCA CTCTCGGCATGGACGAGCTGTACAAGTAAAGGCGCTGAATCGCCAGTGC (SEQ ID NO: 46)
stopGFP	AATTCATGGATGTAAGTAGGTAGTGAGCAAGGGGAGGAGCTGTTACCGGGTGGTGCCCATCTTGGTGGAGCTGGACGGCGACGTAAACGGCCACAAG TTCAGCGTGTCCGGGAGGGGAGGGCGATGCCACCTACGGCAAGCTGACCCCTGAAGTTTCATCTGCACCACCGGCAAGCTGCCCGTGCCTGGCCCAACCCCT CGTGACCACCCCTGACCTACGGGTGCAGTGTCTCAGCCCTACCCCGACACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCGGAAGGCTACGTCC AGGAGCGCACCATCTTCAAGGACGACGGCAACTACAAGACCCGCGGAGTGAAGTTCGAGGGGACACCCCTGGTGAACCGCATCGAGCTGAAGGGC ATCGACTTCAAGGAGGACGGCAACATCTTGGGGACAAGCTGGAGTACAATACAAGCCACAACGTTCTATATCATGGCCGACACGAGAAGAACGGCAT CAAGGTGAACCTCAAGATCCGCCACAACATCGAGGACGGCAGCTGAGTCCCGACCACTACCAGCAGAACACCCCATCGGGCAGGCCCTGCTGC TGCCCCACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAACCCCAACGAGAAGCGGATCACATGGTCTTCTGTGGAGTTCGTGACCCGCCCGGGG ATCACTCTCGGCATGGACGAGCTGTACAAGTAAAGCGGCCCTGAATCGCCAGTGC (SEQ ID NO: 47)
GFP1	AATTCATGGATGTAAGTAGGTAGTGAGCAAGGGGAGGAGCTGTTACCGGGTGGTGCCCATCTTGGTGGAGCTGGACGGCGACGTAAACGGCCACAAG TTCAGCGTGTCCGGGAGGGGAGGGCGATGCCACCTACGGCAAGCTGACCCCTGAAGTTTCATCTGCACCACCGGCAAGCTGCCCGTGCCTGGCCCAACCCCT CGTGACCACCCCTGACCTACGGGTGCAGTGTCTCAGCCCTACCCCGACACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCGGAAGGCTACGTCC AGGAGCGCACCATCTTCAAGGACGACGGCAACTACAAGACCCGCGGAGTGAAGTTCGAGGGGACACCCCTGGTGAACCGCATCGAGCTGAAGGGC AATTCACCTTCAAGGAGGACGGCAACATCTTGGGGACAAGCTGGAGTACAATACAAGCCACAACGTTCTATATCATGGCCGACACGAGAAGAACGGCAT CAAGGTGAACCTCAAGATCCGCCACAACATCGAGGACGGCAGCTGAGTCCCGACCACTACCAGCAGAACACCCCATCGGGCAGGCCCTGCTGC TGCCCCACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAACCCCAACGAGAAGCGGATCACATGGTCTTCTGTGGAGTTCGTGACCCGCCCGGGG ATCACTCTCGGCATGGACGAGCTGTACAAGTAAAGCGGCCCTGAATCGCCAGTGC (SEQ ID NO: 48)
GFP2	AATTCATGGATGTAAGTAGGTAGTGAGCAAGGGGAGGAGCTGTTACCGGGTGGTGCCCATCTTGGTGGAGCTGGACGGCGACGTAAACGGCCACAAG TTCAGCGTGTCCGGGAGGGGAGGGCGATGCCACCTACGGCAAGCTGACCCCTGAAGTTTCATCTGCACCACCGGCAAGCTGCCCGTGCCTGGCCCAACCCCT CGTGACCACCCCTGACCTACGGGTGCAGTGTCTCAGCCCTACCCCGACACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCGGAAGGCTACGTCC AGGAGCGCACCATCTTCAAGGACGACGGCAACTACAAGACCCGCGGAGTGAAGTTCGAGGGGACACCCCTGGTGAACCGCATCGAGCTGAAGGGC AATTCACCTTCAAGGAGGACGGCAACATCTTGGGGACAAGCTGGAGTACAATACAAGCCACAACGTTCTATATCATGGCCGACACGAGAAGAACGGCAT CAAGGTGAACCTCAAGATCCGCCACAACATCGAGGACGGCAGCTGAGTCCCGACCACTACCAGCAGAACACCCCATCGGGCAGGCCCTGCTGC TGCCCCACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAACCCCAACGAGAAGCGGATCACATGGTCTTCTGTGGAGTTCGTGACCCGCCCGGGG CACATGGTCTTGTGGAGTTCGTGACCCGCCCGGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAAAGCGGCCCTGAATCGCCAGTGC (SEQ ID NO: 49)
H2B	ATGCCAGGCCAGGAAAGTCTGCTCCCGCCCGGAAAAGGGCTCCAAAGAGGGGTGACTAAGGGCAGAGAAGGGGCAAGAGCCGAAGCCGAGCCGCG CAAGGAGAGCTATTCCATCTATGTGTACAAGTTCTGAAGCAGGTCCACCTGACACCCGGCATTTTCGTCCAAGGCCATGGGATCATGAATTCGTTTGTGA ACGACATTTTCGAGCGCATCGCAGGTGAGGCTCCCGCCTGGCGCATTAACAACAGCGCTCGACCATCACTCCAGGGAGATCCAGACGGCCGTGGCCCTG CTGTGCTTGGGGAGTTGGCCCAAGCACGCCCTGTCCGAGGGTACTAAGGGCGGTACCAAGGTACACCAGCGGCTAAG (SEQ ID NO: 50)

Spacer	Sequence
	AATTCTAA TAGTGACCAC TCCTGGCTA AATTTTGTATTTT CAGTAGAGATAGGGTTT CACTATGTTGGCCAGGCTGGTCTCCA ACTCCTGACCC TAAAGTGA TCCACCCAC CTTGGTTTCCCAA AGTGCTGGGATACAGGCGTGAGCCACCGTGCC TGGACATAATCTATCTTTTTTTTTTTTGAGATGGAGTCTCGCTCT GTTGCCCA GGTGGAGTGCAGTGGCGTGATTTGGCTCACTGCAACCTCCGCTCCCGGTTCAAGTGATTTCTCTGCCCTAGCCTCCCAAGTAGCTGAGA TTACAGAC GTGGCTCACCATGCCCAAGCTAATTTTGTATTTT TAGTAGAGATGGGATTTTCACTA GTTTGGCCAGGCTGGTCTCGTACTCCCGACCTCAGGT GATCCACT TGGCTTGGCTCCCAAAGTCTGGAAATTACAGG GTGAGCCACTGCATCCGGCCTTATATCTA TCTTGTCTGTGACTGCTAAATCTAAT TCAATCTA TTTTATCTGTTTATCTTAACTAATCATCTATTTA TCTAATCTATCTGTGTA GTCGTGTTTTTTTTTTTTTTTTTTTTTTTTTTTGAGATAGAG TCTTGCTCTGTCGCCGAGGCTGGAGTGGGC (SEQ ID NO: 55)
iCD42	AATTCTAA TAGTGACCAC TCCTGGCTA AATTTTGTATTTT CAGTAGAGATAGGGTTT CACTATGTTGGCCAGGCTGGTCTCCA ACTCCTGACCC TAAAGTGA TCCACCCAC CTTGGTTTCCCAA AGTGCTGGGATACAGGCGTGAGCCACCGTGCC TGGACATAATCTATCTTTTTTTTTTTTGAGATGGAGTCTCGCTCT GTTGCCCA GGTGGAGTGCAGTGGCGTGATTTGGCTCACTGCAACCTCCGCTCCCGGTTCAAGTGATTTCTCTGCCCTAGCCTCCCAAGTAGCTGAGA TTACAGAC GTGGCTCACCATGCCCAAGCTAATTTTGTATTTT TAGTAGAGATGGGATTTTCACTA GTTTGGCCAGGCTGGTCTCGTACTCCCGACCTCAGGT GATCCACT TGGCTTGGCTCCCAAAGTCTGGAAATTACAGG GTGAGCCACTGCATCCGGCCTTATATCTA TCTTGTCTGTGACTGCTAAATCTAAT TCAATCTA TTTTATCTGTTTATCTTAACTAATCATCTATTTA TCTAATCTATCTGTGTA GTCGTGTTTTTTTTTTTTTTTTTTTTTTTTTTTGAGATAGAG TCTTGCTCTGTCGCCGAGGCTGGAGTGGGC (SEQ ID NO: 55)
iCD43	AATTCTAA TAGTGACCAC TCCTGGCTA AATTTTGTATTTT CAGTAGAGATAGGGTTT CACTATGTTGGCCAGGCTGGTCTCCA ACTCCTGACCC TAAAGTGA TCCACCCAC CTTGGTTTCCCAA AGTGCTGGGATACAGGCGTGAGCCACCGTGCC TGGACATAATCTATCTTTTTTTTTTTTGAGATGGAGTCTCGCTCT GTTGCCCA GGTGGAGTGCAGTGGCGTGATTTGGCTCACTGCAACCTCCGCTCCCGGTTCAAGTGATTTCTCTGCCCTAGCCTCCCAAGTAGCTGAGA TTACAGAC GTGGCTCACCATGCCCAAGCTAATTTTGTATTTT TAGTAGAGATGGGATTTTCACTA GTTTGGCCAGGCTGGTCTCGTACTCCCGACCTCAGGT GATCCACT TGGCTTGGCTCCCAAAGTCTGGAAATTACAGG GTGAGCCACTGCATCCGGCCTTATATCTA TCTTGTCTGTGACTGCTAAATCTAAT TCAATCTA TTTTATCTGTTTATCTTAACTAATCATCTATTTA TCTAATCTATCTGTGTA GTCGTGTTTTTTTTTTTTTTTTTTTTTTTTTTTGAGATAGAG TCTTGCTCTGTCGCCGAGGCTGGAGTGGGC (SEQ ID NO: 56)

[00134] **The spacer sequence determines the additive effects of miRNA hairpin concatenation.** To confirm the role of the spacer sequence in the concatenation potency of the vector, multi-hairpin constructs were designed with different spacers: GFP, GFP2, MGST2 or H2B (Fig. 3a). When the GFP or GFP2 sequence was used as a spacer, the concatenation of three hairpins dramatically enhanced CCR5 knockdown compared to a single hairpin construct (from 60% to 85% CCR5 knockdown) (Fig. 3b and 3c). When MGST2 was used as a spacer, substantially different results were obtained. With a single hairpin, the MGST2 sequence had a good spacer activity, albeit not as potent as the GFP sequence (FIG. 2). No additive effect of a three-hairpin concatenation was observed, however, with MGST2 as the spacer (concatenation efficiency close to 1) (Fig. 3c). Thus, there is a dissociation between the spacer potency with a single hairpin, as compared to the concatenation activity. While the former is in a comparable range for GFP and MGST2, the latter is virtually absent with MGST2 as a spacer (Fig. 3c). The opposite was observed with H2B as a spacer: a rather poor knockdown was observed with a single hairpin (~10%), while there was an improved concatenation effect as judged by the CCR5 knockdown with the triple hairpin construct (40% knockdown) (Fig. 3b and 3c). To investigate whether this observation also applies to hairpins targeting genes other than CCR5, a triple hairpin SMIG was constructed, targeting the NOX subunit p22^{phox} (CYBA) with either MGST2 or GFP as spacer sequences (Fig 3d and 3e; see also Fig. 7). These constructs were used to transduce the promyelocytic leukemia cell line PLB-985, which upon differentiation towards a neutrophil-like phenotype, expresses all phagocyte NADPH oxidase subunits (including NOX2 and p22^{phox}/CYBA) and produces reactive oxygen species (ROS) through this NADPH oxidase. There was a 50% decrease in the CYBA mRNA level using the MGST2 spacer/triple hairpin constructs, while with a GFP spacer CYBA mRNA knockdown was >80% (Fig. 3d). Functional activity of the phagocyte NADPH oxidase was assessed, namely ROS generation (Fig. 3e). The production of ROS was inhibited by 60% with the GFP-triple hairpin concatenate targeting p22^{phox}. In contrast, by replacing GFP with MGST2 as a spacer, ROS production was inhibited by no more than 20%. These data confirm that, although efficient knockdown is seen with a single hairpin, the MGST2 spacer has poor concatenation activity (Fig. 3c and Fig. 8). These experiments demonstrate that the spacer sequence is not only required for the knockdown efficiency with a single hairpin but is also required for the additive concatenation effect - the concatenation potency.

[00135] Translation-independent activity of the GFP spacer in cell lines and tissue explants. Among the tested candidates, the GFP sequence was most efficient as a spacer, both with respect to knockdown potency with a single hairpin and concatenation potency. Other coding sequences also yielded some significant knockdown activity, though the CD4 intron
5 was inactive. A construct harboring stop codons in each possible reading frame was generated in order to test whether protein translation of GFP was required for optimal functioning of the SMIG (Fig. 4a). No fluorescence was detected in the cells transduced with stopGFP (Figure 4b). The CCR5 knockdown achieved with the stopGFP spacer was comparable to knockdown with the standard GFP spacer (~50% with a single hairpin construct). These results show that
10 protein translation of the spacer is not important for the function of SMIG, and they provide highly efficient spacer which does not lead to translation of the xenogene GFP and is therefore compatible with a future clinical use.

[00136] To demonstrate the therapeutic potential of the optimized SMIG including the stopGFP spacer, knockdown of the inner ear NADPH oxidase NOX3 was investigated, a
15 potential therapeutic application. This reactive oxygen species (ROS)-producing NADPH oxidase has been shown to be a relevant source of ROS leading to inner ear damage, and it is hence an attractive knockdown target for inner ear protection²⁶. A triple miRGE concatenate was designed, targeting the NOX3 subunit p22^{phox}, under the control of the UBI promoter, and with stopGFP as a spacer. To identify transduced cells, the mCherry coding sequence under
20 the control of the PGK promoter was also included in the construct. Newborn rat cochlear explants were transduced with this construct (Fig. 4d). A dose response for vector transduction using RT PCR to detect and quantify the lentiviral GAG gene (Fig. 4e). Transduced cells could also be identified by mCherry red fluorescence (Fig. 4d; green fluorescence is a marker for hair cells). A minority of hair cells were transduced with the vector under the experimental
25 conditions, but results showed a dose-dependent decrease in p22^{phox} mRNA, confirming the efficiency of the miRGE vector with a second clinically relevant target gene (Fig. 4f).

[00137] Sustained miRNA-mediated knockdown of CCR5 in circulating leukocytes derived from human hematopoietic stem cells: To further demonstrate the in vivo efficacy and the therapeutic potential of the optimized SMIG including the stopGFP
30 spacer, another promising clinical application was investigated, namely knockdown of the HIV co-receptor CCR5 in vivo (FIG. 11). For this purpose, human CD34+ hematopoietic stem cells (HSCs) were transduced with a triple miRGE concatenate, targeting CCR5, under the control

of an elongation factors promoter, and with stopGFP as a spacer. To identify transduced cells, the mCherry coding sequence under the control of the PGK promoter was also included in the construct. After transduction, HSCs were engrafted in NGS (NOD scid gamma) mice following irradiation (FIG. 11A), achieving an engraftment rate varying between 12.4% and 44%, after
5 23 weeks (FIG. 12). 28 weeks following the engraftment, CCR5 expression was investigated in the circulating blood (FIG. 11; 13). The results revealed two kinds of CD4+ T cells with respect to CCR5 expression in untransduced control and mCherry-negative cells (FIGS. 11B and 11C). The proportion of high CCR5-expressing CD4 T cells varied from less than 10% to more than 50% with an average close to 25% in five of the six engrafted animals (FIG. 11D, see mCherry and untransduced ctrl). Note that in one of the six engrafted animals, the high
10 CCR5 CD4 T cells population was virtually absent and therefore not taken into account in FIG. 11D. Importantly, a dramatic decrease of the CCR5 expression level was observed in the mCherry+ transduced population (FIG. 5D, mCherry+).

[00138] The spacer sequence regulates the steady state levels, but not the half-life of miRGE. PCR primers were designed to quantify unprocessed miRGE hairpins (pri-miRGE) (Fig. 5a) or the mature miRGE (Fig 5e) . As seen in Fig. 5b and c, relative expression of the miRGE pri-miRNA was significantly stronger in cells transduced with the stopGFP spacer than in the cells transduced with the MGST-2 or NGFR-based vector. Note that miRGE expression was below the detection threshold with the CD4 first intron as spacer, as also seen
20 in the absence of a spacer. To investigate whether this increase in the steady state levels of miRGE was due to a prolonged half-life of the transcript, HeLa R5 cells were treated with Actinomycin D for different time periods to block transcription (Fig. 5d). mRNA was harvested and miRGE expression levels assessed by qPCR of the pri-miRGE at the different time points. Results showed an estimated miRGE half-life of approximately 30 min with the stopGFP spacer
25 (Fig. 5d), similar to that seen with the NGFR and MGST spacers. The steady state level of the mature miRGE demonstrated that stopGFP spacer allows the best expression of the mature miRGE (Fig. 5f). This observation was also valid when comparing stopGFP and MGST2 spacers with triple hairpin concatenates (Fig 5g). Interestingly, both levels of precursor and mature miRGE were similarly impacted by the spacer sequence. These results strongly suggest
30 that spacer activity is not linked to stability of miRNA transcript nor processing. Rather these results suggest a mechanism where the spacer is relevant for the transcription of the SMIG.

[00139] **Maximizing concatenation and achieving multi-target gene knockdown.** To further investigate the possibility of a multi-target gene knockdown vector with a single promoter-driven miRNA cluster, a fourth and a fifth mirGE hairpin, either targeting CCR5 or a second target gene (GFP in this case), was added to the triple CCR5 construct (Fig. 6a). Concatenation of the hairpins led to a significant increase of the mature miRGE steady state level as a function of the number of hairpins present in the concatenate (Fig. 6b). Interestingly, the addition of a fourth hairpin targeting CCR5, while leading to the highest mature miRGE level, did not provide additional decrease in CCR5 expression compared to the triple hairpin construct arguing for a possible saturation of the CCR5 target sites with the miRGE (Fig. 6c). On the other hand, when the fourth hairpin was replaced with a hairpin targeting GFP, not only did CCR5 knockdown remain at its maximum level (~90%), but there was also a significant decrease in GFP fluorescence (Fig. 6c). Thus, while the hairpin in the fourth position did not further enhance CCR5 knockdown, it was clearly still efficiently processed, as witness by the GFP knockdown (Fig. 6d) and the mature miRGE-GFP steady state level (Fig 6e). Interestingly, a fifth hairpin targeting GFP displayed similar knockdown efficiency and level of mature miRGE as the fourth, still without affecting knockdown of the CCR5. More importantly, miRGE_GFP steady state levels as well as GFP knockdown mediated by the fourth or the fifth miRGE hairpins was comparable to knockdown achieved with a single miRGE hairpin targeting GFP. Thus, with UBI as promoter and stopGFP as spacer, there was no loss of activity with up to five concatenated hairpins. However, the efficiency of the five-hairpin concatenation strongly depended on the spacer. Indeed, the use of MGST2 as spacer led to a dramatic decrease of the fourth and fifth hairpin GFP knockdown potency (Fig. 6f). These data demonstrate that optimized SMIG architecture allows for efficient multi-target gene knockdown upon a single promoter-driven, multi-hairpin construct.

25 **EXAMPLE 3 – PROPHETIC SYNTHETIC MINIGENES FOR IMMUNE CHECKPOINT KNOCKDOWN**

[00140] **Re-direction of immunotherapeutic cells with intrinsic immune checkpoint knockdown.** Depicted in FIG. 10 is a schematic of a prophetic synthetic minigene which may be used to knockdown immune check points. The synthetic minigene is comprised of a promoter sequence, spacer sequence, at least 2 miRNA hairpins, and a chimeric antigen receptor sequence or T cell receptor sequence. The synthetic minigene may optionally comprise a selection sequence, such as a low-affinity nerve growth factor receptor (LNGFR) or suicide gene sequence. Further, in order to express the miRNA hairpins, CAR or TCR sequence, and

selection sequence equally, the CAR or TCR sequence may be separated from the selection sequence by a “cleavable peptide” such as a 2A sequence, or T2A sequence. These synthetic minigenes may comprise miRNA hairpin sequences directed to any immune checkpoint. Specifically, the miRNA hairpin sequences may target PD1, CTLA4, LAG3, TIM3, TIGIT, CD96, BTLA, KIRs, adenosine A2a receptor, Vista, IDO, FAS, SIRP alpha, CISH, SHP-1, FOXP3, LAIR1, PVRIG, PPP2CA, PPP2CB, PTPN6, PTPN22, CD160, CRTAM, SIGLEC7, SIGLEC9, CD244, TNFRSF10B, TNFRSF10A, CASP8, CASP10, CASP3, CASP6, CASP7, FADD, TGFBR2, TGFBR1, SMAD2, SMAD3, SMAD4, SMAD10, SKI, SKIL, TGIF1, IL10RA, IL10RB, HMOX2, IL6R, IL6ST, EIF2AK4, CSK, PAG1, SIT1, PRDM1, BATF, GUCY1A2, GUCY1A3, GUCY1B2, and GUCY1B3 mRNA. The promoter used may be any mammalian promoter, such as EF1s or UBI, or any promoter listed in Table 1. The spacer sequence may be any length or sequence, particularly one of the spacers listed in Table 9. Any immune effector cell may be targeted with these miRNA expression constructs. Specifically, T cells, tumor infiltrating lymphocytes (TILs), TCR-engineered T cells, CAR T cells, NK cells, or T regulatory cells may be engineered with the synthetic miRNA constructs.

[00141] Tumor infiltrating lymphocytes with intrinsic immune checkpoint knockdown may be generated using the synthetic minigenes provided herein. To generate these TILs with immune checkpoint knockdown, TILs may be isolated from the patients’ tumor tissue and purified. These purified TILs may be transduced with a lentiviral vector comprising a therapeutic minigene harboring miRNA hairpins directed to immune checkpoint mRNAs in order to knock down the gene expression of one or more immune checkpoints. Then, the modified TILs may be expanded *ex vivo*, and finally re-introduced to the patient.

[00142] CAR T cells or TCR engineered T cells with intrinsic immune checkpoint knockdown may be generated similarly to TILs. T cells can be collected from patients by leukapheresis. The collected cells may then be transduced with a single vector comprising the miRNA hairpins targeting the immune checkpoint mRNAs as well as the CAR or engineered TCR sequence. Having these in a single vector, as shown in FIG. 10, allows for a more efficient turn-around time from T cell collection to patient treatment. Alternatively, the collected T cells may be treated with two separate vectors. The first vector may comprise the CAR or engineered TCR sequence, and may be transduced or transfected into the cells. The second vector then comprises a lenti vector harboring the miRNA expression construct with the miRNA hairpins targeted to the immune checkpoint mRNAs. Following transduction of the

second vector, these modified T cells may be expanded *ex vivo* and later re-introduced to the patient.

EXAMPLE 4 – SYNTHETIC MINIGENES TARGET GENE KNOCKDOWN

5 *Single and double hairpin mirGE constructs knockdown CCR5 with high efficiency in HeLaR5 cells*

[00143] Using an optimized therapeutic minigene architecture (EF1s promoter, GFP2 spacer, single and double CCR5-targeting mirGE hairpins were constructed to evaluate how efficiently they could downregulate CCR5 relative to our established three-hairpin construct (FIG. 14). HeLaR5 cells were transduced with lentiviral vectors carrying the
10 constructs at a MOI of 1.0, and CCR5 downregulation measured 5-7 days following transduction. All constructs also carried an mCherry reported gene to identify transduced cells. CCR5 knockdown was measured *via* flow cytometry by measuring the MFI of transduced cells (mCherry positive) vs untransduced cells within the same sample, and this ratio compared relative to HeLaR5 cells transduced with a control lentiviral vector to express mCherry only.

15 [00144] Results indicated high efficiency downregulation of CCR5 with all three constructs, as demonstrated by significant reductions in MFI and an overall shift in fluorescent intensity when compared to cells transduced with the control vector (FIG 14B). Relative CCR5 expression levels were 16.5%, 15% and 15.7% (mean of n=6) for the single, double and triple hairpin constructs, respectively. Notably, maximal CCR5 knockdown in HeLaR5 cells can be
20 achieved with a single mirGE hairpin when using the our optimized therapeutic minigene architecture (EF1s promoter, GFP2 spacer).

High efficiency knockdown of PD1 in primary T cells

[00145] Considering the central role that PD1 plays in T exhaustion, and more broadly in the field of engineered T cell therapies, a therapeutic minigene was developed that
25 would maximally downregulate PD1. Three mirGE constructs to silence PD1 were designed according the approach described previously (Myburgh *et al.*, 2014, incorporated herein by reference). Target sequences were identified using online software tools, including i-Score Designer, BLOCK-iT (ThermoFisher), GeneScript siRNA Target Finder, and siDESIGN Center (Dharmacon). Based on the scoring of these tools, a list of top 10 target sequences was
30 generated. The target sequences were then each screened for homology across the human

genome using BLAST, and those with >70% homology to any other gene were excluded. Finally, three target sequences were selected (Table 10) for cloning into the mirGE and our optimized therapeutic minigene architecture (EF1s promoter, GFP2 spacer). Once constructed, the three minigenes were packaged into lentiviral vectors and used to transduce primary T cells from two healthy donors at a MOI of 1.0 and 2.5. All constructs also carried a mCherry reported gene to identify transduced cells. PD1 expression levels were measured 5-7 days after transduction using flow cytometry. Since PD1 is not expressed uniformly, nor constitutively on primary T cells, we first determined the percentage of PD1-expressing T cells, and then compared the MFI of the PD1-expressing cells relative to control transduced (mCherry only) T cells.

Table 10. PD1 target sequences

Identifier	Target sequence
PD1-1A (SEQ ID NO: 59)	CGGAGAGCTTCGTGCTAAA
PD1-2A (SEQ ID NO: 60)	CCAACACATCGGAGAGCTT
PD1-3A (SEQ ID NO: 61)	CCAGCAACCAGACGGACAA

[00146] The initial screen for target sequences which could be accessible for mirGE knockdown resulted in one of the three candidates showing significant effect (PD1-1A). As can be seen in examples of the flow cytometry dot plots and histograms (FIG. 15B-C), there was an evident shift in fluorescent intensity of cells transduced with PD1-1A mirGE, which was not the case in T cells transduced with PD1-2A and 3A. PD1-1A transduced T cells had a mean reduction in PD1-expressing cells of 27% (FIG. 15D), while those transduced with PD1-2A and PD1-3A constructs had a 12% and 9% reduction ($p=0.047$, Kruskal-Wallis ANOVA). Moreover, within the PD1-expressing T cell population, there was a 48% reduction in PD1 expression in cells transduced with the PD1-1A construct (FIG. 15E), while T cells transduced with PD1-2A and 3A constructs had a 3% and 14% reduction ($p<0.001$, Kruskal-Wallis ANOVA).

[00147] Thus, the PD1-1A mirGE was applied for further development of two and three hairpin constructs in an attempt to achieve maximal knockdown of PD1 (FIG. 16). Using T cells harvested from the same donor as used before, we transduced and evaluated PD1 knockdown according to the experimental plan shown in FIG. 16A. Flow cytometry data (FIG. 16 B-C) indicated that further PD1 downregulation can be achieved with two and three hairpin

mirGE constructs, but that maximal knockdown was achieved with two hairpins (since there was a negligible difference when using the three hairpin construct). Both the two and three hairpin constructs reduced the proportion of PD1-expressing cells by 45% relative to the control vector, while also downregulating PD1 expression on the PD1-expressing cells by
5 nearly 40% (FIG. 16D-E).

PD1 knockdown in CAR T cells protects against T cell exhaustion

[00148] To evaluate if PD1-targeting constructs would be protected against T cell exhaustion, anti-cKit CAR T cells transduced and co-cultured these cells with HL-60 tumor cells at effector:target (E:T) ratios of 1:15 and 1:30 over a four day period. A pure population
10 of anti-cKit CAR T cells (previously selected) were thawed and transduced 24 hours later at a MOI of 1.0 with lentivectors carrying a three-hairpin mirGE therapeutic minigene against PD1. Co-culturing was initiated with 100,000 CAR T cells (anti-cKit with and without PD1 knockdown), and 1.5 million and 3.0 million HL-60 tumor cells added to achieve the 1:15 and 1:30 E:T ratios, respectively. A negative control group of CAR T cells only (not co-cultured
15 with target cells) was also included. All conditions were cultured in medium not containing IL-2, made up with Advanced RPMI, 10% FBS, 1% pen-strep and 1x glutamax. After four days of co-culturing, cells were harvested for counting and flow cytometric analysis of PD1 expression on CD3 positive T cells.

[00149] A transduction rate of ~20% was achieved in the anti-cKit CAR T cells
20 transduced with our PD1-targeting therapeutic minigene (based on mCherry positivity). On Day 4, the transduction rate was assessed again in the negative control group, which was reported to be 18.6% (FIG. 18A). When the proportion of mCherry positive cells was assessed in the 1:15 and 1:30 E:T ratio groups, there was a 1.5 fold increase (relative to the negative control, FIG. 18B), indicating that PD1 knockdown CAR T cells were proliferating at a higher
25 rate than CAR T cells without PD1 knockdown. Negative control CAR T cells expanded from 100,000 to 4.7 million over the four day period (FIG. 18C). In the groups without PD1 knockdown, anti-cKit CAR T cells expanded to 2.3 million and 1.7 million at 1:15 and 1:30 E:T ratio conditions, respectively. In the groups that had ~20% PD1 knockdown CAR T cells at the outset, cell counts of 3.2 million and 2.3 million were recorded for the 1:15 and 1:30 E:T
30 ratio conditions, respectively. Together with the fact that the proportion of mCherry positive cells increased 1.5 fold, it was therefore apparent that CAR T cells without PD1 knockdown were exhausted more rapidly, leading to a decrease in proliferation and/or cell death. These

data were confirmed when we evaluated the fold increase for both E:T conditions and, specifically, for the mCherry positive CAR T cell population (based on the 1.5 fold proportion at Day 4). When compared to the anti-cKit CAR T cell group (without a ~20% PD1 knockdown sub-population), CAR T cells with PD1 knockdown had a proliferation rate of more than
5 double at the 1:15 E:T ratio (23 vs 48-fold), and approximately twice at the 1:30 ratio (17 vs 33-fold).

[00150] PD1 knockdown in mCherry transduced CAR T cells was confirmed *via* flow cytometric analysis (FIG. 18E). As can be seen in the dot plots, the PD1-expressing population of CAR T cells is substantially decreased when compared to the untransduced CAR
10 T cell population within the same sample (mCherry negative), as well as relative to the CAR T cell group that were not transduced with a mirGE therapeutic minigene. This effect was observed in both the 1:15 and 1:30 experimental groups, and which aligns with our PD1 knockdown data reported previously herein. When comparing the 1:15 and 1:30 E:T conditions with overlaid flow cytometric dot plots and aligned histograms (FIG. 18F), it
15 became evident that CAR T cells in the 1:30 condition expressed an overall higher frequency of PD1 based on fluorescent intensity and PD1 expressing cells, providing indication that these CAR T cells were considerably more exhausted than those with PD1 knockdown. Finally, the percentage of PD1-expressing CAR T cells was evaluated from the two E:T conditions (FIG. 18G). At the 1:15 E:T ratio, both groups of CAR T cell had a median 20% PD1-expressing
20 cells. Bearing in mind that PD1 knockdown CAR T cells made up ~28% of this population (having increased 1.5 fold over the four day period), it is apparent that these cells helped rescue the overall CAR T cell population within these samples. This rescue effect is more evident in the 1:30 condition, where nearly 70% of CAR T cells without PD1 knockdown were PD1 positive, but which decreased to below 40% in the group that started with ~20% CAR T cells
25 with PD1 knockdown.

Multi-target mirGE hairpins maintain efficiency of CCR5 knockdown

[00151] To evaluate if up to six mirGE hairpins could be expressed with optimized therapeutic minigene architecture (EF1s promoter, GFP2 spacer), a multi-target hairpin construct against PD1, GFP and CCR5 was constructed (FIG. 17A). The potential
30 impact of CCR5 knockdown if the mirGE targeting CCR5 were positioned terminally in the therapeutic minigenes was evaluated. Studies were undertaken to determine if there be a decrease in CCR5 knockdown if the CCR5-targeting hairpins were at positions 3 and 4 within

a four-hairpin construct. Similarly, it was evaluated if placement of these hairpins in positions 5 and 6 impact CCR5 knockdown. In order to test this, HeLaR5 cells were transduced with these constructs and evaluated CCR5 downregulation relative to a two-hairpin CCR5 targeting vector as well as a control vector (mCherry only). CCR5 knockdown was evaluated using flow
5 cytometry. Results indicated negligible differences in the downregulation of CCR5 ($p=0.135$, Kruskal-Wallis ANOVA), which was 85%, 81% and 82% for the two-hairpin, four-hairpin and six-hairpin constructs, respectively (FIG. 17B-C). These data, together with those showing the high efficiency of single-hairpin mirGE against CCR5 and PD1, substantiate the use of our therapeutic minigene technology for targeting at least two clinically relevant genes for
10 downregulation.

Four hairpin therapeutic minigenes effectively downregulate PD1 and CCR5 in primary T cells

[00152] Using a four-hairpin mirGE construct (two hairpins against PD1, two against CCR5), primary T cells were transduced as described before and evaluated for
15 knockdown of these two clinically relevant target genes. Five days after transduction, PD1 and CCR5 expression was assessed via flow cytometry (FIG. 19). Indeed, a significant reduction in both PD1 and CCR5 expressing cells were observed. In the overlaid dot plots and histograms, a substantial decrease in CCR5 and PD1 was observed (FIG. 19A and 19B). By plotting CCR5 vs PD1 and overlaying mCherry positive and mCherry negative populations
20 (FIG. 19C), an evident decrease in the CCR5+PD1+ population was observed in T cells transduced with the 4 hairpin mirGE construct (notably exposing the CCR5+PD1+ population of untransduced T cells, *i.e.* dots in upper right decades of the dot plot). These data indicate that our mirGE therapeutic minigenes are able to efficiently knockdown the expression of two clinically relevant target genes.

25

* * *

[00153] All of the methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be
30 apparent to those of skill in the art that variations may be applied to the methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain

agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

5

REFERENCES

The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by
5 reference.

- Aiuti *et al.*, *Science*, 341: 1233151, 2013.
Biffi *et al.*, *Science*, 341: 1233158, 2013.
Boudreau *et al.*, *RNA*, 14:1834-1844, 2008.
10 Boudreau *et al.*, *Mol Ther*, 17:169-175, 2009
Bourhill *et al.*, *J Virol Methods*, 235: 26-33, 2016.
Fowler *et al.*, *Nucleic Acids Res*, 44: e48, 2016.
Giry-Laterriere *et al.*, *Hum Gene Ther*, 22: 1255-1267, 2011.
Giry-Laterriere *et al.*, *Methods in molecular biology*, 737: 183-209, 2011.
15 Grimm, *Silence 2*: 8, 2011.
Hu *et al.*, *Mol Biotechnol*, 46: 34-40, 2010.
Jaquet *et al.*, *Br J Pharmacol*, 164: 507-520, 2011
Lee *et al.*, *Embo J* 23: 4051-4060, 2004.
Liu *et al.*, *Nucleic Acids Res*, 36:2811-2824, 2008.
20 Liu and Berkhout, *Methods Mol Biol*, 942: 233-257, 2013.
Maczuga *et al.*, *Mol. Ther.*, 21: 217-227, 2013.
Mottet-Osman *et al.*, *J Virol*, 81:2861-2868, 2007.
Myburgh *et al.*, *Molecular Therapy Nucleic Acids*, 3: e207, 2014.
Osorio *et al.*, *J Biotechnol*, 169: 71-81, 2014.
25 Ruby *et al.*, *Nature*, 448: 83-86, 2007.
Seyhan, *Mol Biosyst*, 12: 295-312, 2016.
Sibley *et al.*, *Nucleic Acids Res*, 40: 9863-9875, 2012.
Stegmeier *et al.*, *PNAS*, 102: 13212-13217, 2005.
Sullenger and Nair, *Science*, 352: 1417-1420, 2016.
30 Sun, D *et al.*, *Biotechniques*, 41: 59-63, 2006.
Winter *et al.*, *Nat. Cell. Biol.*, 11: 228-234., 2009.
Yang *et al.*, *Mol Ther*, 21: 588-601, 2013.

CLAIMS

What is Claimed is:

1. A miRNA expression construct comprising, from 5' to 3', a promoter element, a spacer between 300 and 600 nucleotides in length, and at least one miRNA hairpin, wherein the spacer has a sequence at least 80% identical to SEQ ID NO: 49.
2. The miRNA expression construct of claim 1, wherein the promoter is a eukaryotic Pol II or Pol III promoter.
3. The miRNA expression construct of claim 2, wherein the promoter has a sequence at least 80%, 85%, 90% or 95% identical to SEQ ID NO: 45.
4. The miRNA expression construct of any one of claims 1-3, wherein the miRNA hairpin comprises from 5' to 3' and in the order from (a)-(g):
 - (a) a mir-16 flanking sequence comprising the sequence of SEQ ID NO: 25;
 - (b) a first lower stem sequence comprising the mir-16 sequence of SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29 or SEQ ID NO: 30;
 - (c) an anti-sense target sequence 22 nucleotides in length;
 - (d) a mir-30 loop sequence comprising the sequence of SEQ ID NO: 31;
 - (e) a sense sequence wherein the sequence is complementary to the sequence of (c) except that the sequence comprises one or two mismatches relative to the sequence of (c), wherein the one or two mismatches comprise:
 - i) a mismatch located at the position 8 to 14 of the sense sequence, optionally located at position 11 of the sense sequence; and/or
 - ii) a mismatch at the final 3' position (position 22) of the sense sequence;
 - (f) a second lower stem sequence wherein the sequence is complementary to the sequence of (b); and
 - (g) a second flanking sequence, optionally wherein flanking sequence (g) is not complementary to the mir-16 flanking sequence (a).
5. The miRNA expression construct of any one of claims 1-4, wherein the nucleic acid molecule is RNA.

6. The miRNA expression construct of any one of claims 1-4, wherein the nucleic acid molecule is DNA.
7. The miRNA expression construct of any one of claims 1-6, comprising at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 miRNA hairpins.
8. The miRNA expression construct of claim 7, wherein at least two of the miRNA hairpins target the same sequence.
9. The miRNA expression construct of claim 7, wherein at least two of the miRNA hairpins target different sequences.
10. The miRNA expression construct of any one of claims 1-9, wherein the miRNA expression construct further comprises a chimeric antigen receptor sequence or a T cell receptor sequence.
11. The miRNA expression construct of any one of claims 1-10, wherein the miRNA expression construct further comprises a selection gene and/or a suicide gene.
12. The miRNA expression construct of any one of claims 1-11, wherein the miRNA expression construct further comprises a peptide cleavage site.
13. A vector comprising the miRNA expression construct of any one of claims 1-12.
14. A mammalian cell comprising the miRNA expression construct of any one of claims 1-12 or the vector of claim 13.
15. The mammalian cell of claim 14, wherein the mammalian cell is an immune effector cell.
16. A method for preparing engineered immune effector cells comprising transfecting or transducing the immune effector cells with the miRNA expression construct of any one of claims 1-12 or transducing the immune effector cells with the vector of claim 13.
17. The method of claim 16, comprising transducing or transfecting the immune effector cells with a chimeric antigen receptor or T cell receptor.

18. A method of treating a patient in need thereof, comprising introducing the cells of claim 14 or 15 into the patient.




FIG. 1




FIG. 2




FIG. 3




FIG. 5




FIG. 6




FIG. 7




FIG. 8

Concatenation potency = CP (%)
 Knockdown potency = KP (%)

E = Concatenation efficiency with 3 hairpins

$$CP = (KP)^E$$

If E=3 concatenation efficiency is 100%

$$E = \ln(CP) / \ln(KP)$$

If E=1 concatenation efficiency is 0%

FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19

UGEN_P0020WO_ST25.TXT
SEQUENCE LISTING

<110> University of Geneva et al.

<120> MICRO RNA EXPRESSION CONSTRUCTS AND USES THEREOF

<130> UGEN.P0020WO

<150> 62/650403
<151> 2018-03-30

<150> 62/650387
<151> 2018-03-30

<160> 58

<170> PatentIn version 3.5

<210> 1
<211> 56
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 1
ggggacaagt ttgtacaaaa aagcaggctg aattctgagc aagggcgagg agctgt 56

<210> 2
<211> 57
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 2
ggggaccact ttgtacaaga aagctgggtc tcgagcttgt acagctcgtc catgccg 57

<210> 3
<211> 60
<212> DNA
<213> Artificial Sequence

<220>

UGEN_P0020WO_ST25.TXT

<223> Primer

<400> 3

ggggacaagt ttgtacaaaa aagcaggctt ctagaatgga tgtaagtagg tgagtgagca 60

<210> 4

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 4

ggggaccact ttgtacaaga aagctgggctc tcgagcttgt acagctcgtc catgccgaga 60

<210> 5

<211> 56

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 5

ggggacaagt ttgtacaaaa aagcaggctg aattctgagc aagggcgagg agctgt 56

<210> 6

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 6

gggggctcga gtcgccctcg aacttcacct cg 32

<210> 7

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 7

ggggggaatt ccaccctggt gaaccgcatc ga

32

<210> 8

<211> 57

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 8

ggggaccact ttgtacaaga aagctgggtc tcgagcttgt acagctcgtc catgccg

57

<210> 9

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 9

ggggaccact ttgtacaaga aagctgggtc tcgagctaga ggatccccct gttccacct

59

<210> 10

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 10

ggggacaagt ttgtacaaaa aagcaggctg aattctcacc atgggggcag gtgccaccgg

60

<210> 11

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

UGEN_P0020WO_ST25.TXT

<223> Primer

<400> 11

ggggacaagt ttgtacaaaa aagcaggctg aattctcacc atggagcgtc cgcaaccga 60

<210> 12

<211> 49

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 12

ggggaccact ttgtacaaga aagctgggctc tacagcaact gtcgccacc 49

<210> 13

<211> 84

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 13

ggggacaagt ttgtacaaaa aagcaggctg aattctaata gtgaccactc ctggctaatt 60

tttgtatttt cagtagagat aggg 84

<210> 14

<211> 79

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 14

ggggaccact ttgtacaaga aagctgggctc tcgagggtga aacccttctc tactaaaaat 60

acaaaattag ccgggcaca 79

<210> 15

<211> 75

UGEN_P0020WO_ST25.TXT

<212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 15
 ggggaccact ttgtacaaga aagctgggtc tcgagccgca ctccagcctc ggcgacagag 60
 caagactcta tctca 75

<210> 16
 <211> 75
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 16
 ggggaccact ttgtacaaga aagctgggtc tcgagtcggg agtacgagac cagcctggcc 60
 aacatagtga aatcc 75

<210> 17
 <211> 56
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 17
 ggggacaagt ttgtacaaaa aagcaggctg aattcatgcc agagccagcg aagtc 56

<210> 18
 <211> 56
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 18
 ggggaccact ttgtacaaga aagctgggtc tcgaggtgta cttggtgacg gcctta 56

UGEN_P0020WO_ST25.TXT

<210> 19
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 19
cagaagggga tccatcgata ctagtgggta tagcaatgtc agcagtcct 50

<210> 20
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 20
agtagcttct agagtagagt atgggtcaacc ttactt 36

<210> 21
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 21
cagaagggga tccggtgata gcaatgtcag cagtcct 38

<210> 22
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 22
agtagctact agttagagt atgggtcaacc ttactt 36

<210> 23
 <211> 38
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Primer

 <400> 23
 cagaaggctc gaggtgata gcaatgtcag cagtcct 38

<210> 24
 <211> 36
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Primer

 <400> 24
 agtagctgga tccgtagagt atggtcaacc ttactt 36

<210> 25
 <211> 12
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> mir-16

 <400> 25
 ggtgatagca at 12

<210> 26
 <211> 11
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Lower stem

 <400> 26
 cagcagtgcc t 11

<210> 27
 <211> 12
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Lower stem

 <400> 27
 tcagcagtgc ct 12

<210> 28
 <211> 13
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Lower stem

 <400> 28
 gtcagcagtg cct 13

<210> 29
 <211> 14
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Lower stem

 <400> 29
 cgtcagcagt gcct 14

<210> 30
 <211> 15
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Lower stem

 <400> 30
 acgtcagcag tgcct 15

UGEN_P0020WO_ST25.TXT

<210> 31
 <211> 15
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Lower stem

 <400> 31
 gtgaagccac agatg 15

 <210> 32
 <211> 107
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> miRGE CCR5-7

 <400> 32
 ggtgatagca atgtcagcag tgccttcata gattggactt gacacttgtg aagccacaga 60
 tgaagtgtca agcccaatct atgcaagtaa ggttgacat actctac 107

 <210> 33
 <211> 107
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> miRGE GFP

 <400> 33
 ggtgatagca atgtcagcag tgcctagttc accttgatgc cgttcttgtg aagccacaga 60
 tgaagaacgg caccaagtg aaccaagtaa ggttgacat actctac 107

 <210> 34
 <211> 107
 <212> DNA
 <213> Artificial Sequence

 <220>

UGEN_P0020WO_ST25.TXT

<223> miRGE p22phox

<400> 34

ggtgatagca atgtcagcag tgcctacatg gccactcga tctgcccgtg aagccacaga 60

tggggcagat cgcgtgggcc atgcaagtaa gttgacat actctac 107

<210> 35

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 35

tggacgtttc acacagtgg 20

<210> 36

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 36

tggaccctt tttcctctt 20

<210> 37

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 37

ggtgatagca atgtcagcag tgcct 25

<210> 38

<211> 23

<212> DNA

<213> Artificial Sequence

<220>
 <223> Primer

<400> 38
 gtagagtatg gtcaacctta ctt 23

<210> 39
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 39
 ggagctagaa cgattcgcag tta 23

<210> 40
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 40
 ggttgtagct gtcccagtat ttgtc 25

<210> 41
 <211> 19
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 41
 tccacttggt cgctttgct 19

<210> 42
 <211> 23
 <212> DNA
 <213> Artificial Sequence

UGEN_P0020WO_ST25.TXT

<220>
 <223> Primer

<400> 42
 cttcttgacc acagctttga tga 23

<210> 43
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 43
 tccatgacaa ctttggcatt g 21

<210> 44
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 44
 cagtcttctg ggtggcagtg a 21

<210> 45
 <211> 248
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> EF1 promoter

<400> 45
 cgatggctcc ggtgcccgtc agtgggcaga gcgcacatcg cccacagtcc ccgagaagtt 60
 ggggggaggg gtcggcaatt gaaccggtgc ctagagaagg tggcgcgggg taaactggga 120
 aagtgatgtc gtgtactggc tccgcctttt tcccagggtt gggggagaac cgtatataag 180
 tgtagtagtc gccgtgaac ttctttttcg caacgggttt gccgccagaa cacaggtgtc 240

UGEN_P0020WO_ST25.TXT

gtgacgcg 248

<210> 46
 <211> 758
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Spacer

<400> 46
 atggatgtaa gtaggtgagt gagcaagggc gaggagctgt tcaccggggt ggtgcccac 60
 ctggtcgagc tggacggcga cgtaaacggc cacaagttca gcgtgtccgg cgagggcgag 120
 ggcgatgcca cctacggcaa gctgaccctg aagttcatct gcaccaccgg caagctgccc 180
 gtgccctggc ccaccctcgt gaccaccctg acctacggcg tgcaagtgtt cagccgctac 240
 cccgaccaca tgaagcagca cgacttcttc aagtccgcca tgcccgaagg ctacgtccag 300
 gagcgcacca tcttcttcaa ggacgacggc aactacaaga cccgcgccga ggtgaagttc 360
 gagggcgacc accctgggtga accgcatcga gctgaagggc atcgacttca aggaggacgg 420
 caacatcctg gggcacaagc tggagtataa ctacaacagc cacaacgtct atatcatggc 480
 cgacaagcag aagaacggca tcaaggtgaa cttcaagatc cgccacaaca tcgaggacgg 540
 cagcgtgcag ctcgccgacc actaccagca gaacaccccc atcggcgacg gccccgtgct 600
 gctgcccgac aaccactacc tgagcaccca gtccgccctg agcaaagacc ccaacgagaa 660
 gcgcatcac atggtcctgc tggagttcgt gaccgccgcc gggatcactc tcggcatgga 720
 cgagctgtac aagtaaagcg gcctgaatcg ccagtgtc 758

<210> 47
 <211> 762
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Spacer

UGEN_P0020WO_ST25.TXT

<400> 47
aattcatgga tgtaagtagg tgagtgagca agggcgagga gctgttcacc ggggtggtgc 60
ccatcctggt cgagctggac ggcgacgtaa acggccacaa gttcagcgtg tccggcgagg 120
gcgagggcga tgccacctac ggcaagctga ccctgaagtt catctgcacc accggcaagc 180
tgcccgtgcc ctggcccacc ctctgacca ccctgaccta cggcgtgcag tgcttcagcc 240
gctaccccga ccacatgaag cagcacgact tcttcaagtc cgccatgccc gaaggctacg 300
tccaggagcg caccatcttc ttcaaggacg acggcaacta caagaccgc gccgaggtga 360
agttcgaggg cgacaccctg gtgaaccgca tcgagctgaa gggcatcgac ttcaaggagg 420
acggcaacat cctggggcac aagctggagt acaactacaa cagccacaac gtctatatca 480
tggccgacaa gcagaagaac ggcatcaagg tgaacttaa gatccgccac aacatcgagg 540
acggcagcgt gcagctgcc gaccactacc agcagaacac ccccatcggc gacggccccg 600
tgctgctgcc cgacaaccac tacctgagca cccagtccgc cctgagcaaa gaccccaacg 660
agaagcgcga tcacatggtc ctgctggagt tcgtgaccgc cgccgggatc actctcggca 720
tggacgagct gtacaagtaa agcggcctga atcgccagtg tc 762

<210> 48
<211> 375
<212> DNA
<213> Artificial Sequence

<220>
<223> Spacer

<400> 48
aattcatgga tgtaagtagg tgagtgagca agggcgagga gctgttcacc ggggtggtgc 60
ccatcctggt cgagctggac ggcgacgtaa acggccacaa gttcagcgtg tccggcgagg 120
gcgagggcga tgccacctac ggcaagctga ccctgaagtt catctgcacc accggcaagc 180
tgcccgtgcc ctggcccacc ctctgacca ccctgaccta cggcgtgcag tgcttcagcc 240
gctaccccga ccacatgaag cagcacgact tcttcaagtc cgccatgccc gaaggctacg 300
tccaggagcg caccatcttc ttcaaggacg acggcaacta caagaccgc gccgaggtga 360

UGEN_P0020WO_ST25.TXT

agttcgaggg cgacc 375

<210> 49
 <211> 394
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Spacer

<400> 49
 aattccacc tggtgaaccg catcgagctg aaggcatcg acttcaagga ggacggcaac 60
 atcctggggc acaagctgga gtacaactac aacagccaca acgtctatat catggccgac 120
 aagcagaaga acggcatcaa ggtgaacttc aagatccgcc acaacatcga ggacggcagc 180
 gtgcagctcg ccgaccacta ccagcagaac acccccatcg gcgacggccc cgtgctgctg 240
 cccgacaacc actacctgag caccagtcg gccctgagca aagaccccaa cgagaagcgc 300
 gatcacatgg tcctgctgga gttcgtgacc gccgccggga tcactctcgg catggacgag 360
 ctgtacaagt aaagcggcct gaatcgccag tgtc 394

<210> 50
 <211> 378
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Spacer

<400> 50
 atgccagagc cagcgaagtc tgctcccgcc ccgaaaaagg gctccaagaa ggcggtgact 60
 aaggcgcaga agaaaggcgg caagaagcgc aagcgcagcc gcaaggagag ctattccatc 120
 tatgtgtaca aggttctgaa gcaggtccac cctgacaccg gcatttcgtc caaggccatg 180
 ggcatcatga attcgtttgt gaacgacatt ttcgagcgca tcgcaggtga ggcttcccgc 240
 ctggcgcatt acaacaagcg ctcgaccatc acctccaggg agatccagac ggccgtgcgc 300
 ctgctgctgc ctggggagtt ggccaagcac gccgtgtccg agggactaa ggccgtcacc 360

UGEN_P0020WO_ST25.TXT

aagtacacca gcgctaag 378

<210> 51
 <211> 854
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Spacer

<400> 51
 aattctcacc atgggggagc gtgccaccgg ccgcgccatg gacgggccgc gcctgctgct 60
 gttgctgctt ctgggggtgt cccttgagg tgccaaggag gcatgccccca caggcctgta 120
 cacacacagc ggtgagtgt gcaaagcctg caacctgggc gagggtgtgg cccagccttg 180
 tggagccaac cagaccgtgt gtgagccctg cctggacagc gtgacgttct ccgacgtggt 240
 gagcgcgacc gagccgtgca agccgtgcac cgagtgcgtg gggctccaga gcatgtcggc 300
 gccgtgcgtg gaggccgacg acgccgtgtg ccgctgcgcc tacggctact accaggatga 360
 gacgactggg cgctgcgagg cgtgccgcgt gtgcgaggcg ggctcgggcc tcgtgttctc 420
 ctgccaggac aagcagaaca ccgtgtgcga ggagtgcccc gacggcacgt attccgacga 480
 ggccaaccac gtggaccctg gcctgccctg caccgtgtgc gaggacaccg agcggcagct 540
 ccgcgagtgc acacgctggg ccgacgccga gtgcgaggag atccctggcc gttggattac 600
 acggtccaca cccccagagg gctcggacag cacagcccc agcaccagc agcctgaggc 660
 acctccagaa caagacctca tagccagcac ggtggcaggt gtggtgacca cagtgatggg 720
 cagctcccag cccgtggtga cccgaggcac caccgacaac ctcattccctg tctattgctc 780
 catcctggct gctgtggttg tgggccttgt ggcctacata gccttcaaga ggtggaacag 840
 ggggatcctc tagc 854

<210> 52
 <211> 730
 <212> DNA
 <213> Artificial Sequence

UGEN_P0020WO_ST25.TXT

<220>

<223> Spacer

<400> 52

aattcggcac gagggacttc tgttccagag caaaggtcat tcagccgctt gaatcagcct	60
tttcccccca cccggtcccc aactttgttt acccgataag gaaggtcagc attcaaagtc	120
aagaagcgcc atttatcttc ccgtgcgctc tacaatagt tccgtgagaa agatggccgg	180
gaactcgatc ctgctggctg ctgtctctat tctctcgcc tgtcagcaaa gttattttgc	240
tttgcaagtt ggaaaggcaa gattaaata caaagttacg cccccagcag tcaactgggtc	300
accagagttt gagagagtat ttcgggcaca acaaaactgt gtggagtttt atcctatatt	360
cataattaca ttgtggatgg ctgggtggta tttcaaccaa gtttttgcta cttgtctggg	420
tctggtgtac atatatggcc gtcacctata cttctgggga tattcagaag ctgctaataa	480
acggatcacc ggtttccgac tgagtctggg gattttggcc ttggtgacct tcctaggtgc	540
cctgggaatt gcaaacagct ttctggatga atatctggac ctcaatattg ccaagaaact	600
gaggcggcaa ttctaacttt ttctcttccc tttaatgctt gcagaagctg ttcccacat	660
gaaggtaata tggtatcatt tgtaaataa aaataaagtc tttattctgt taaaaaaaa	720
aaaaaaaaac	730

<210> 53

<211> 873

<212> DNA

<213> Artificial Sequence

<220>

<223> Spacer

<400> 53

aattcatgga gcgtccgcaa cccgacagca tgccccagga tttgtcagag gccctgaagg	60
aggccaccaa ggaggtgcac acccaggcag agaatgctga gttcatgagg aactttcaga	120
agggccagggt gacccgagac ggcttcaagc tggtgatggc ctccctgtac cacatctatg	180
tggccctgga ggaggagatt gagcgaaca aggagagccc agtcttcgcc cctgtctact	240

UGEN_P0020WO_ST25.TXT

tcccagaaga gctgcaccgc aaggctgccc tggagcagga cctggccttc tggtaggggc 300
cccgtggca ggaggatc cctacacac cagccatgca gcgctatgtg aagcggctcc 360
acgaggtggg gcgcacagag cccgagctgc tggtagggcca cgcctacacc cgctacctgg 420
gtgacctgtc tggggggccag gtgctcaaaa agattgccc gaaagccctg gacctgccc 480
gctctggcga gggcctggcc ttcttcacct tcccacat tgccagtgcc accaagttca 540
agcagctcta ccgctccgc atgaactccc tggagatgac tcccagctc aggcagaggg 600
tgatagaaga ggccaagact gcgttcctgc tcaacatcca gctctttgag gagttgcagg 660
agctgctgac ccatgacacc aaggaccaga gccctcacg ggcaccaggg cttcgccagc 720
gggcccagcaa caaagtgcaa gattctgccc ccgtggagac tcccagaggg aagccccac 780
tcaacaccg ctcccaggct ccgcttctcc gatgggtcct tacactcagc tttctggtgg 840
cgacagttgc tgtagggctt tatgccatgt gac 873

<210> 54
<211> 781
<212> DNA
<213> Artificial Sequence

<220>
<223> Spacer

<400> 54
aattctaata gtgaccactc ctggctaatt tttgtatatt cagtagagat agggtttcac 60
tatgttggcc aggctggtct ccaactcctg acctaaagtg atccaccac cttggtttcc 120
caaagtgctg ggattacagg cgtgagccac cgtgcctgga catatatcta tctttttttt 180
ttttgagatg gagtctcgct ctggtgcca ggctggagtg cagtggcgtg atttcggctc 240
actgcaacct ccgctcccg ggttcaagtg attctcctgc ctcagcctcc caagtagctg 300
agattacaga cgtgcgtcac catgcccagc taatttttgt attttttagta gagatgggat 360
ttcactatgt tggccaggct ggtctcgtac tcccagctc aggtgatcca cttgccttgg 420
cctcccaaag tgctggaatt acaggtgtga gccactgcat ccggccttat atatctatct 480

UGEN_P0020WO_ST25.TXT

tgtctgtctg actgtctaata ctaattcatc tattttatct gtttatctta tctatcatct 540
 atttatctaa tctatctgtc tgtatgtctg tttttttttt gttttttttt tttttttgag 600
 atagagtctt gctctgtcgc cgaggctgga gtgcggtggc gcgatctcag ctcaactgctg 660
 aacctccgcc tcctgggttc taagcgattc tcctgcctca atctttggag tagctgggat 720
 tacaggcccc taccactgtg cccggctaata tttgtatttt tagtagagaa gggtttcacc 780
 c 781

<210> 55
 <211> 637
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Spacer

<400> 55
 aattctaata gtgaccactc ctggctaatt tttgtatttt cagtagagat agggtttcac 60
 tatgttgGCC aggctggctt ccaactcctg acctaaagtG atccaccac cttggtttcc 120
 caaagtgctg ggattacagg cgtgagccac cgtgcctgga catatatcta tctttttttt 180
 ttttgagatg gagtctcgtc ctgttgccca ggctggagtg cagtggcgtg atttcggctc 240
 actgcaacct ccgcctcccg ggttcaagtG attctcctgc ctcaagcctcc caagtagctg 300
 agattacaga cgtgcgtcac catgcccagc taatttttGt atttttagta gagatgggat 360
 ttcactatgt tggccaggct ggtctcgtac tcccgacctc aggtgatcca cttgccttgg 420
 cctcccaaag tgctggaatt acaggtgtga gccactgcat ccggccttat atatctatct 480
 tgtctgtctg actgtctaata ctaattcatc tattttatct gtttatctta tctatcatct 540
 atttatctaa tctatctgtc tgtatgtctg tttttttttt gttttttttt tttttttgag 600
 atagagtctt gctctgtcgc cgaggctgga gtgcggc 637

<210> 56
 <211> 254

UGEN_P0020WO_ST25.TXT

<212> DNA
 <213> Artificial Sequence

<220>
 <223> Spacer

<400> 56
 aattctaata gtgaccactc ctggctaatt tttgtatntt cagtagagat agggttttcac 60
 tatgttggcc aggctggtct ccaactcctg acctaaagtg atccaccac cttggtttcc 120
 caaagtgctg ggattacagg cgtgagccac cgtgcctgga catatatcta tctntttntt 180
 tnttgagatg gagtctcgct ctgntgcca ggctggagtg cagtggcgtg atntcggctc 240
 actgcaacct ccgc 254

<210> 57
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 57
 aagaacggca tcaagtgaa ct 22

<210> 58
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 58
 aagtgtcaag tccaatctat ga 22